Document:

ex_109373.htm

Exhibit 10.2

 

 

Investor rights agreement

 

This Investor Rights Agreement (this “Agreement”) is made and entered into as of March 26, 2018, by and among Giga-tronics Incorporated, a corporation organized in the State of California (the “Company”), and the purchaser identified on the signature page hereto (the “Purchaser”).

 

This Agreement is made pursuant to the Securities Purchase Agreement, dated as of [date], 2018, between the Company and the Purchasers party thereto, relating to the purchase of shares of Preferred Stock (the “Purchase Agreement”).

 

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:

 

1.     Definitions. As used in this Agreement, the following terms shall have the following meanings:

 

“Affiliate” means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act; provided, however, that notwithstanding the foregoing, as used herein, the Purchaser shall not be deemed an Affiliate of the Company or any Subsidiary, and none of the Company and its Subsidiaries shall be deemed an Affiliate of the Purchaser.

 

“Agreement” has the meaning set forth in the preamble.

 

“Blue Sky Filing” has the meaning set forth in Section 6(a).

 

“Business Day” means any day other than Saturday, Sunday or any other day on which commercial banks in the State of California or City of New York are authorized or required by law to remain closed.

 

“Claims” has the meaning set forth in Section 6(a).

 

“Commission” means the United States Securities and Exchange Commission.

 

“Common Shares” means those shares of the Common Stock issuable upon conversion of the Preferred Stock purchased by the Purchaser from the Company under the Purchase Agreement.

 

“Common Stock” means the Company’s common stock, no par value.

 

“Company” has the meaning set forth in the preamble and includes the Company’s successors by merger, acquisition, reorganization or otherwise.

 

 

 

 

“Company Indemnified Party” has the meaning set forth in Section 6(b).

 

“Effective Date” means the date a Registration Statement is declared effective by the Commission.

 

“Effectiveness Deadline” means the date that is 60 days after the date of the Filing Deadline or, if the Commission staff reviews or provides comments on the applicable Registration Statement, 90 days after the date of the Filing Deadline.

 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

 

“Filing Deadline” means 45 days after the Company becomes eligible to file a registration statement with the Commission on Form S-3.

 

“Grace Period” has the meaning set forth in Section 3(j).

 

“Indemnified Damages” has the meaning set forth in Section 6(a).

 

“Initial Registration Statement” has the meaning set forth in Section 2(a).

 

“Legal Counsel” has the meaning set forth in Section 3(c).

 

“Matter” has the meaning set forth in Section 12(a).

 

“New Registration Statement” has the meaning set forth in Section 2(a).

 

“Person” means an individual, corporation, partnership, limited liability company, trust, business trust, incorporated or unincorporated association, joint stock company, joint venture, sole proprietorship, government (or an agency or subdivision thereof), governmental authority or other entity of any kind.

 

“Preferred Stock” means the Company’s 6.0% Series E Senior Convertible Voting Perpetual Preferred Stock.

 

“Prospectus” means the prospectus included in a Registration Statement, as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.

 

“Purchase Agreement” has the meaning set forth in the recitals.

 

“Purchaser” has the meaning set forth in the preamble and includes any transferee or assignee thereof to whom the Purchaser assigns its rights under this Agreement and who agrees to become bound by the provisions of this Agreement in accordance with Section 8 and any transferee or assignee thereof to whom a transferee or assignee assigns its rights under this Agreement and who agrees to become bound by the provisions of this Agreement in accordance with Section 8.

 

2

 

 

“Purchaser Indemnified Party” has the meaning set forth in Section 6(a).

 

“register,” “registered,” and “registration” refer to a registration effected by preparing and filing one or more Registration Statements (as defined below) in compliance with the Securities Act and pursuant to Rule 415 and the declaration or ordering of effectiveness of such Registration Statement(s) by the Commission.

 

“Registrable Securities” means all of the Common Shares and any securities issued or distributed or issuable in respect thereof by way of a stock split, dividend or other distribution or in connection with a combination of shares, recapitalization, merger consolidation or other reorganization or similar event with respect to the Common Shares; provided, that Common Shares shall cease to be Registrable Securities upon the earliest to occur of the following: (A) a sale pursuant to a Registration Statement or Rule 144 (in which case, only such security sold shall cease to be a Registrable Security); (B) if such Common Shares have ceased to be outstanding; (C) if such Common Shares have been sold in a private transaction in which the Purchaser’s rights under this Agreement have not been assigned to the transferee; or (D) such Common Shares are freely transferable under Rule 144 without regard to any further holding period or compliance with other conditions of Rule 144.

 

“Registration Period” has the meaning set forth in Section 3(a).

 

“Registration Statement” means a registration statement or registration statements of the Company filed under the Securities Act covering the Registrable Securities.

 

“Required Holders” means the holders of at least 50% of the Registrable Securities.

 

“Rule 144” means Rule 144 under the Securities Act as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“Rule 415” means Rule 415 under the Securities Act as such Rule may be amended from time to time, or any successor rule providing for offering securities on a continuous or delayed basis.

 

“Rule 424” means Rule 424 under the Securities Act as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“SEC Guidance” means any publicly-available written or oral guidance, comments, requirements or requests of the Commission staff.

 

“Securities Act” means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

 

3

 

 

“Selling Expenses” means all underwriting discounts, selling commissions and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any holder of Registrable Securities, except for the fees and disbursements of counsel for the holders of Registrable Securities required to be paid by the Company pursuant to Section 5.

 

“Special Voting Right Termination Event” has the meaning set forth in the Certificate of Determination with respect to the Preferred Stock.

 

“Subsidiary” means any entity in which the Company, directly or indirectly, owns sufficient capital stock or holds a sufficient equity or similar interest such that it is consolidated with the Company in the financial statements of the Company.

 

“Suspension Notice” has the meaning set forth in Section 4(c).

 

“Underwritten Offering” means a registration in which Registrable Securities are sold to an underwriter or underwriters on a firm commitment basis for reoffering to the public.

 

“Violations” has the meaning set forth in Section 6(a).

 

2.           Registration.

 

a.       The Company agrees to file with the Commission a Registration Statement under the Securities Act on Form S-3, no later than the Filing Deadline, covering the offer and resale of all of the Registrable Securities on a continuous basis pursuant to Rule 415 (the “Initial Registration Statement”). The Company shall use commercially reasonable efforts to have the Registration Statement declared effective by the Commission as soon as practicable, but in no event later than the Effectiveness Deadline. Notwithstanding the registration obligations set forth in the preceding sentences of this Section 2(a), if, in response to its filing of the Initial Registration Statement, the Company receives a Commission comment that all of the Registrable Securities cannot be registered for resale on the Initial Registration Statement, then the Company shall promptly inform the Purchaser thereof and, upon the written request of the Required Holders, either (i) file amendments to the Initial Registration Statement, or (ii) withdraw the Initial Registration Statement and file a new registration statement (a “New Registration Statement”), in either case covering the maximum number of Registrable Securities consistent with such Commission comment, and, as promptly as practicable thereafter, taking into account such Commission comment, file a Registration Statement covering the balance of the Registrable Securities; provided, in no event shall the Company be required to file a registration statement on Form S-1 or equivalent long-form registration statement. The registration obligation will be deferred for so long as the Company is not eligible to file on Form S-3. The Company will use its best efforts to regain and retain Form S-3 eligibility. In no event shall the Company include any securities other than Registrable Securities on any Registration Statement under this Section 2 without the prior written consent of the Required Holders.

 

4

 

 

b.       Ineligibility for Form S-3. The Initial Registration Statement shall be on Form S-3 notwithstanding the registration obligations set forth in third sentence of Section 2(a). In the event that Form S-3 is at any time not available for the registration of the resale of Registrable Securities, the Company shall undertake to file with the Commission a Registration Statement on Form S-3 to register the Registrable Securities within 30 days of the date on which the Company’s use of Form S-3 first becomes available, provided that the Company shall maintain the effectiveness of any Registration Statement then in effect until such time as a new Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by the Commission.

 

c.        Effectiveness. The Company shall cause any Registration Statement filed under Section 2 to be declared effective under the Securities Act as promptly as possible after the filing thereof. 

 

d.        [intentionally omitted].

 

e.         Underwritten Offering.

 

(i)       If the holders of not less than a majority of any class of Registrable Securities included in any offering pursuant to a Registration Statement filed pursuant to Section 2 so elect, such offering shall be in the form of an Underwritten Offering and the Company, if necessary, shall amend or supplement such Registration Statement for such purpose. The holders of a majority of the class of Registrable Securities included in such Underwritten Offering shall, after consulting with the Company, have the right to select the managing underwriter or underwriters for the offering.

 

(ii)      In the case of an Underwritten Offering pursuant to Section 2.e(i), the Company shall cause the senior executive officers of the Company to participate in the customary “road show” presentations that may be reasonably requested by the managing underwriter in any such Underwritten Offering and otherwise to facilitate, cooperate with, and participate in each proposed offering contemplated herein and customary selling efforts related thereto using commercially reasonable efforts (provided, that such activities shall not unreasonably interfere with the duties of such officers in the ordinary course of the Company’s business).

 

(iii)     In the case of an Underwritten Offering pursuant to Section 2.e(i), the Company shall cooperate with the selling holders of Registrable Securities and the managing underwriter, underwriters or agent, if any, using commercially reasonable efforts to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be sold and not bearing any restrictive legends.

 

3.          Registration Procedures. At such time as the Company is obligated to file a Registration Statement with the Commission pursuant to Section 2, the Company will use reasonable best efforts to effect the registration of the Registrable Securities in accordance with the intended method of disposition thereof and, pursuant thereto, the Company shall have the following obligations:

 

a.       The Company shall keep each Registration Statement effective pursuant to Rule 415 at all times from its effective time until the earlier of (i) the date as of which the Common Stock covered by such Registration Statement cease to be Registrable Securities or (ii) the date on which the Purchaser shall have sold all of the Registrable Securities covered by such Registration Statement (the “Registration Period”). The Company shall ensure that each Registration Statement (including any amendments or supplements thereto and Prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein (in the case of Prospectuses, in the light of the circumstances in which they were made) not misleading.

 

5

 

 

b.      The Company shall prepare and file with the Commission such amendments and supplements to a Registration Statement and the Prospectus used in connection with such Registration Statement, which Prospectus is to be filed pursuant to Rule 424 promulgated under the Securities Act, as may be necessary to keep such Registration Statement effective at all times during the Registration Period, and, during such period, comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities of the Company covered by such Registration Statement until such time as all of such Registrable Securities shall have been disposed of in accordance with the intended methods of disposition by the seller or sellers thereof as set forth in such Registration Statement. In the case of amendments and supplements to a Registration Statement that are required to be filed pursuant to this Agreement (including pursuant to this Section 3(b)) by reason of the Company filing a report on Form 10-Q, Form 10-K or any analogous report under the Exchange Act, the Company shall have incorporated such report by reference into such Registration Statement, if applicable, or shall file such amendments or supplements with the Commission on the same day on which the Exchange Act report is filed which created the requirement for the Company to amend or supplement such Registration Statement.

 

c.      The Purchaser shall have the right to select one legal counsel to review and oversee any registration pursuant to this Agreement (“Legal Counsel”), as designated by the Required Holders. The Company and Legal Counsel shall reasonably cooperate with each other in performing the Company’s obligations under this Agreement. The Company shall (A) permit Legal Counsel to review and comment upon (i) a Registration Statement at least five (5) Business Days prior to its filing with the Commission and (ii) all amendments and supplements to all Registration Statements (except for Annual Reports on Form 10-K, and Reports on Form 10-Q and any similar or successor reports) within a reasonable number of days prior to their filing with the Commission, and (B) not file any Registration Statement or amendment or supplement thereto in a form to which Legal Counsel reasonably objects. The Company shall not submit a request for acceleration of the effectiveness of a Registration Statement or any amendment or supplement thereto without the prior approval of Legal Counsel, which consent shall not be unreasonably withheld. The Company shall promptly furnish to Legal Counsel, without charge, (i) copies of any correspondence from the Commission or the staff of the Commission to the Company or its representatives relating to any Registration Statement, (ii) after the same is prepared and filed with the Commission, one copy of any Registration Statement and any amendment(s) thereto, including financial statements and schedules, all documents incorporated therein by reference, if requested by the Purchaser, and all exhibits and (iii) upon the effectiveness of any Registration Statement, one copy of the Prospectus included in such Registration Statement and all amendments and supplements thereto. The Company shall reasonably cooperate with Legal Counsel in performing the Company’s obligations pursuant to this Section 3.

 

6

 

 

d.     The Company shall promptly furnish to the Purchaser, without charge, (i) after the same is prepared and filed with the Commission, at least one copy of such Registration Statement and any amendment(s) thereto, including financial statements and schedules, all documents incorporated therein by reference, if requested by the Purchaser, all exhibits and each preliminary Prospectus, (ii) upon the effectiveness of any Registration Statement, ten (10) copies of the Prospectus included in such Registration Statement and all amendments and supplements thereto (or such other number of copies as the Purchaser may reasonably request) and (iii) such other documents, including copies of any preliminary or final Prospectus, as the Purchaser may reasonably request from time to time in order to facilitate the disposition of the Registrable Securities owned by the Purchaser.

 

e.     The Company shall (i) register and qualify, unless an exemption from registration and qualification applies, the resale by the Purchaser of the Registrable Securities covered by a Registration Statement under such other securities or “blue sky” laws of all applicable jurisdictions in the United States, (ii) prepare and file in those jurisdictions, such amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such other actions as may be necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (x) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(e), (y) subject itself to general taxation in any such jurisdiction, or (z) file a general consent to service of process in any such jurisdiction. The Company shall promptly notify Legal Counsel and the Purchaser of the receipt by the Company of any notification with respect to the suspension of the registration or qualification of any of the Registrable Securities for sale under the securities or “blue sky” laws of any jurisdiction in the United States or its receipt of actual notice of the initiation or threatening of any proceeding for such purpose.

 

f.     The Company shall notify Legal Counsel and the Purchaser in writing of the happening of any event, as promptly as practicable after becoming aware of such event, as a result of which the Prospectus included in a Registration Statement, as then in effect, includes an untrue statement of a material fact or omission to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading (provided that in no event shall such notice contain any material, nonpublic information), and, subject to Section 3(j), promptly prepare a supplement or amendment to such Registration Statement to correct such untrue statement or omission, and deliver ten (10) copies of such supplement or amendment to Legal Counsel and the Purchaser (or such other number of copies as Legal Counsel or the Purchaser may reasonably request). The Company shall also promptly notify Legal Counsel and the Purchaser in writing (i) when a Prospectus or any Prospectus supplement or post-effective amendment has been filed, and when a Registration Statement or any post-effective amendment has become effective (notification of such effectiveness shall be delivered to Legal Counsel and the Purchaser by facsimile on the same day of such effectiveness and by overnight mail), (ii) of any request by the Commission for amendments or supplements to a Registration Statement or related Prospectus or related information, and (iii) of the Company’s reasonable determination that a post-effective amendment to a Registration Statement would be appropriate.

 

7

 

 

g.     The Company shall use commercially reasonable efforts to prevent the issuance of any stop order or other suspension of effectiveness of a Registration Statement, or the suspension of the qualification of any of the Registrable Securities for sale in any jurisdiction and, if such an order or suspension is issued, to obtain the withdrawal of such order or suspension at the earliest possible moment and to notify Legal Counsel and the Purchaser of the issuance of such order and the resolution thereof or its receipt of actual notice of the initiation or threat of any proceeding for such purpose.

 

h.     The Company shall hold in confidence and not make any disclosure of information concerning the Purchaser provided to the Company unless (i) disclosure of such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information is necessary to avoid or correct a misstatement or omission in any Registration Statement, (iii) the release of such information is ordered pursuant to a subpoena or other final, non-appealable order from a court or governmental body of competent jurisdiction, or (iv) such information has been made generally available to the public other than by disclosure in violation of this Agreement or any other agreement. The Company agrees that it shall, upon learning that disclosure of such information concerning the Purchaser is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt written notice to the Purchaser and allow the Purchaser, at the Purchaser’s expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information.

 

i.     If requested by the Purchaser, the Company shall (i) as soon as practicable incorporate in a Prospectus supplement or post-effective amendment such information as the Purchaser reasonably requests to be included therein relating to the sale and distribution of Registrable Securities, including, without limitation, information with respect to the number of Registrable Securities being offered or sold, the purchase price being paid therefor and any other terms of the offering of the Registrable Securities to be sold in such offering; (ii) as soon as practicable make all required filings of such Prospectus supplement or post-effective amendment after being notified of the matters to be incorporated in such Prospectus supplement or post-effective amendment; and (iii) as soon as practicable, supplement or make amendments to any Registration Statement if reasonably requested by the Purchaser holding any Registrable Securities.

 

j.     Notwithstanding anything to the contrary herein, at any time after the Effective Date, the Company may delay the disclosure of material, non-public information concerning the Company the disclosure of which at the time is not, in the good faith opinion of the Board of Directors of the Company and its counsel, in the best interest of the Company and, in the opinion of counsel to the Company, otherwise required (a “Grace Period”); provided, that the Company shall promptly (i) notify the Purchaser in writing of the existence of material, non-public information giving rise to a Grace Period (provided that in each notice the Company will not disclose the content of such material, non-public information to the Purchaser) and the date on which the Grace Period will begin, and (ii) notify the Purchaser in writing of the date on which the Grace Period ends; and, provided further, that no Grace Period shall exceed sixty (60) consecutive days and during any three hundred sixty five (365) day period such Grace Periods shall not exceed an aggregate of one hundred twenty (120) days and the first day of any Grace Period must be at least two (2) trading days after the last day of any prior Grace Period. For purposes of determining the length of a Grace Period above, the Grace Period shall begin on and include the date the Purchaser receives the notice referred to in clause (i) and shall end on and include the later of the date the Purchaser receives the notice referred to in clause (ii) and the date referred to in such notice. The provisions of Section 3(g) hereof shall not be applicable during the period of any Grace Period. Upon expiration of the Grace Period, the Company shall again be bound by the first sentence of Section 3(f) with respect to the information giving rise thereto unless such material, non-public information is no longer applicable. Notwithstanding anything to the contrary, the Company shall cause its transfer agent to deliver unlegended shares of Common Stock to a transferee of the Purchaser in connection with any sale of Registrable Securities with respect to which such Purchaser has entered into a contract for sale, and delivered a copy of the Prospectus included as part of the applicable Registration Statement (unless an exemption from such prospectus delivery requirements exists), prior to the Purchaser’s receipt of the notice of a Grace Period and for which the Purchaser has not yet settled.

 

8

 

 

4.           Obligations of the Purchaser Relating to Registration.

 

a.       At least ten Business Days prior to the first anticipated filing date of a Registration Statement, the Company shall notify the Purchaser in writing of the information the Company requires from the Purchaser to have any of the Purchaser’s Registrable Securities included in such Registration Statement. It shall be a condition precedent to the obligations of the Company to complete the registration pursuant to this Agreement with respect to the Registrable Securities of the Purchaser that the Purchaser shall furnish to the Company, not later than five Business Days after the date of the Company’s notice, such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required to effect the effectiveness of the registration of the Purchaser’s Registrable Securities.

 

b.       The Purchaser, by its acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of any Registration Statement hereunder, unless such Purchaser has notified the Company in writing of its election to exclude all of such Purchaser’s Registrable Securities from such Registration Statement.

 

c.       The Purchaser agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 3(g) or the first sentence of Section 3(f) (each a “Suspension Notice”), the Purchaser will immediately discontinue disposition of Registrable Securities pursuant to any Registration Statement(s) covering such Registrable Securities until the Purchaser’s receipt of the copies of the supplemented or amended Prospectus contemplated by Section 3(g) or the first sentence of Section 3(f) or receipt of notice that no supplement or amendment is required. Notwithstanding anything to the contrary, the Company shall cause its transfer agent to deliver unlegended shares of Common Stock to a transferee of the Purchaser in accordance with the terms of the Purchase Agreement in connection with any sale of Registrable Securities with respect to which such Purchaser has entered into a contract for sale prior to such Purchaser’s receipt of a notice from the Company of the happening of any event of the kind described in Section 3(g) or the first sentence of Section 3(f) and for which the Purchaser has not yet settled. In any event, the Company shall not be entitled to deliver more than one Suspension Notice in any one year.

 

9

 

 

d.       The Purchaser covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable to it or an exemption therefrom in connection with sales of Registrable Securities pursuant to the Registration Statement.

 

5.           Expenses of Registration. All expenses, other than Selling Expenses, with respect to the registration and disposition of Registrable Securities including, without limitation, all registration, listing and qualifications fees, printers and accounting fees, and fees and disbursements of counsel for the Company and reasonable fees (which shall be proportional and reasonable in relation to the market value of the Registrable Securities being registered) of one counsel for the Purchaser, who shall be selected by the Required Holders shall be paid by the Company. All Selling Expenses relating to Registrable Securities registered pursuant to this Agreement shall be borne and paid by the holders of such Registrable Securities, in proportion to the number of Registrable Securities registered for each such holder.

 

6.           Indemnification. In the event any Registrable Securities are included in a Registration Statement under this Agreement:

 

a.       To the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend the Purchaser, the directors, officers, managers, members, partners, employees, agents, representatives of, and each Person, if any, who controls the Purchaser within the meaning of the Securities Act or the Exchange Act (each, a “Purchaser Indemnified Party”), against any losses, claims, damages, liabilities, judgments, fines, penalties, charges, costs, attorneys’ fees, amounts paid in settlement or expenses, joint or several, (collectively, “Claims”) incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency, body or the Commission, whether pending or threatened, whether or not an indemnified party is or may be a party thereto (“Indemnified Damages”), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in a Registration Statement or any amendment thereof or supplement thereto or in any filing made in connection with the qualification of the offering under the securities or other “blue sky” laws of any jurisdiction in which Registrable Securities are offered (“Blue Sky Filing”), or the omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) any untrue statement or alleged untrue statement of a material fact contained in any Prospectus or free writing prospectus (as defined in Rule 405 under the Securities Act), or the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in the light of the circumstances under which the statements therein were made, not misleading, or (iii) any violation of this Agreement (the matters in the foregoing clauses (i) through (iii) being, collectively, “Violations”). Subject to Section 6(c), the Company shall reimburse the Purchaser Indemnified Parties, promptly as such expenses are incurred and are due and payable, for any legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 6(a): shall not apply to a Claim (a) arising out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the Company by or on behalf of such Purchaser Indemnified Party expressly for use in any Prospectus or supplement thereto or the omission or alleged omission in such written information to state a material fact required to be stated therein or necessary to make the statements therein not misleading, if such Prospectus or supplement thereto was timely made available by the Company pursuant to Section 3(d); (b) to the extent such Claim is based on a failure of such Purchaser Indemnified Party to deliver or to cause to be delivered the Prospectus made available by the Company, including a corrected Prospectus, if such Prospectus or corrected Prospectus was timely made available by the Company pursuant to Section 3(d); (c) in which amounts are paid in settlement of any Claim and such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld or delayed; (d) in which such Purchaser Indemnified Party fails to cease all offers and sales of Registrable Securities in accordance with Section 4(c) herein, to the extent such Claim is based on such failure; and (e) arising out of or based solely upon a breach by such Purchaser Indemnified Party of such Purchaser Indemnified Party’s obligations set forth herein. This indemnity shall be in addition to any liability the Company may otherwise have. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Purchaser Indemnified Party and shall survive the transfer of the Registrable Securities by the Purchaser pursuant to Section 8. 

 

10

 

 

b.     In connection with any Registration Statement in which the Purchaser is participating, to the fullest extent permitted by law, such Purchaser agrees to severally and not jointly indemnify, hold harmless and defend the Company and each of its directors, officers, employees, agents and representatives and each Person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act (each, an “Company Indemnified Party”), against any Claim or Indemnified Damages to which any of them may become subject, under the Securities Act, the Exchange Act or otherwise, insofar as such Claim or Indemnified Damages arise out of or are based upon (i) any untrue statement or alleged untrue statement of a material fact in a Registration Statement or any amendment thereof or supplement thereto or in any filing made in connection with a Blue Sky Filing, or the omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii) any untrue statement or alleged untrue statement of a material fact contained in any Prospectus or free writing prospectus (as defined in Rule 405 under the Securities Act), or the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in the light of the circumstances under which the statements therein were made, not misleading, in each case to the extent, and only to the extent, that such untrue statement or omission of a material fact is contained in any written information furnished to the Company by such Purchaser expressly for use in connection with such Registration Statement; and, subject to Section 6(c), such Purchaser will reimburse any legal or other expenses reasonably incurred by an Company Indemnified Party in connection with investigating or defending any such Claim; provided, however, that the indemnity agreement contained in this Section 6(b) and the agreement with respect to contribution contained in Section 7 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of such Purchaser, which consent shall not be unreasonably withheld or delayed and provided further, that the obligation to indemnify shall be limited to the net proceeds (after underwriting fees, commissions or discounts) actually received by such holder from the sale of Registrable Securities pursuant to such Registration Statement. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Company Indemnified Party and shall survive the transfer of the Registrable Securities by the Purchaser pursuant to Section 8.

 

11

 

 

c.     Promptly after receipt by a Purchaser Indemnified Party or Company Indemnified Party under this Section 6 of notice of the commencement of any action or proceeding (including any governmental action or proceeding) involving a Claim, such Purchaser Indemnified Party or Company Indemnified Party shall, if a Claim in respect thereof is to be made against any indemnifying party under this Section 6, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Purchaser Indemnified Party or the Company Indemnified Party, as the case may be; provided, however, that a Purchaser Indemnified Party or Company Indemnified Party shall have the right to retain its own counsel with the fees and expenses of not more than one counsel for such Purchaser Indemnified Party or Company Indemnified Party to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of the Purchaser Indemnified Party or Company Indemnified Party and the indemnifying party would be inappropriate due to actual or potential differing interests between such Purchaser Indemnified Party or Company Indemnified Party and any other party represented by such counsel in such proceeding. In the case of a Purchaser Indemnified Party, legal counsel referred to in the immediately preceding sentence shall be selected by the Required Holders. The Company Indemnified Party or Purchaser Indemnified Party shall cooperate fully with the indemnifying party in connection with any negotiation or defense of any such action or Claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Company Indemnified Party or Purchaser Indemnified Party which relates to such action or Claim. The indemnifying party shall keep the Company Indemnified Party or Purchaser Indemnified Party reasonably apprised at all times as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its prior written consent, provided, however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the prior written consent of the Company Indemnified Party or Purchaser Indemnified Party, consent to entry of any judgment or enter into any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Company Indemnified Party or Purchaser Indemnified Party of a release from all liability in respect to such Claim or litigation, and such settlement shall not include any admission as to fault on the part of the Company Indemnified Party. Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Company Indemnified Party or Purchaser Indemnified Party with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Purchaser Indemnified Party or Company Indemnified Party under this Section 6, except to the extent that the indemnifying party is prejudiced in its ability to defend such action.

 

12

 

 

d.     The indemnification required by this Section 6 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or Indemnified Damages are incurred.

 

e.     The indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Company Indemnified Party or Purchaser Indemnified Party against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant to the law.

 

7.         Contribution. To the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law; provided, however, that: (i) no Person involved in the sale of Registrable Securities which Person is guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) in connection with such sale shall be entitled to contribution from any Person involved in such sale of Registrable Securities who was not guilty of fraudulent misrepresentation; and (ii) contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds received by such seller from the sale of such Registrable Securities pursuant to such Registration Statement. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties' relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The parties agree that it would not be just and equitable if contribution pursuant hereto were determined by pro rata allocation or by any other method or allocation which does not take account of the equitable considerations referred to herein.

 

8.         Assignment of Registration Rights. The registration rights provided pursuant to Sections 2 through 10 of this Agreement shall be assignable in full or in part by the Purchaser to any transferee of such Purchaser’s Registrable Securities if: (i) the Purchaser agrees in writing with the transferee or assignee to assign such rights, and a copy of such agreement is furnished to the Company within a reasonable time after such assignment; (ii) the Company is, contemporaneous with such transfer or assignment, furnished with written notice of (a) the name and address of such transferee or assignee, and (b) the Registrable Securities with respect to which such registration rights are being transferred or assigned; and (iii) at or before the time the Company receives the written notice contemplated by clause (ii) of this sentence the transferee or assignee agrees in writing with the Company to be bound by all of the provisions contained herein.

 

9.         Amendment. Provisions of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Required Holders (or, in the case of an amendment to or wavier of the second sentence of Section 12 adversely affecting the rights of holders of Preferred Stock, the holders of two-thirds of the outstanding shares of Preferred Stock then outstanding). Any amendment or waiver effected in accordance with this Section 9 shall be binding upon the Purchaser and the Company. No such amendment shall be effective to the extent that it applies to less than all of the holders of the Registrable Securities.

 

13

 

 

10.      Preservation of Rights.   Except with the prior consent of the Required Holders, the Company shall not, for so long as there are Registrable Securities, (a) grant any registration rights to third parties that are inconsistent with the rights granted hereunder, or (b) enter into any agreement, take any action, or permit any change to occur, with respect to its securities that violates or subordinates the rights expressly granted to the holders of Registrable Securities in this Agreement.

 

11.      Rule 144 Compliance.   With a view to making available to the holders of Registrable Securities the benefits of Rule 144 under the Securities Act and any other rule or regulation of the Commission that may at any time permit a holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3 (or any successor form), the Company shall:

 

a.         make and keep public information available, as those terms are understood and defined in Rule 144 at all times; and

 

b.        use its commercially reasonable best efforts to file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act.

 

12.      Voting Rights. Each Purchaser shall have the voting rights of a holder of the Preferred Stock as set forth in the Certificate of Determination for the Preferred Stock. In addition, until a Special Voting Right Termination Event occurs, the Company shall not incur or issue any additional debt, other than trade debt incurred in the normal course and commercial bank working capital debt, whether revolving or term debt, without the approval of the holders of at least two-thirds of outstanding shares of Preferred Stock then outstanding.

 

13.      Miscellaneous.

 

a.     A Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed to own of record such Registrable Securities.

 

b.     Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally, (ii) upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party), so long as such facsimile is followed by mail delivery of the same information contained in such facsimile, or (iii) one Business Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses for such communications shall be:

 

14

 

 

If to the Company:             Giga-tronics Incorporated

5990 Gleason Drive

Dublin CA 94568

Attn: John Regazzi

Email: jregazzi@gigatronics.com

 

If to the Purchaser, to the address set forth underneath the Purchaser’s name on the signature page hereto. 

 

Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication, or (B) provided by a courier or overnight courier service shall be rebuttable evidence of personal service, or receipt from a nationally recognized overnight delivery service in accordance with clause (i) or (iii) above, respectively.

 

c.     Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof.

 

d.     All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of California, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of California or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of California.

 

e.     This Agreement and the instruments referenced herein constitute the entire agreement among the parties hereto with respect to the subject matter hereof and thereof. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein and therein. This Agreement and the instruments referenced herein supersede all prior agreements and understandings among the parties hereto with respect to the subject matter hereof and thereof.

 

f.     Subject to the requirements of Section 8, this Agreement shall inure to the benefit of and be binding upon the permitted successors and assigns of each of the parties hereto.

 

g.     The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.

 

h.     This Agreement may be executed in identical counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement. This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

 

i.     Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

15

 

 

j.     All consents and other determinations required to be made by the Purchaser pursuant to this Agreement shall be made, unless otherwise specified in this Agreement, by the Required Holders.

 

k.     The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent and no rules of strict construction will be applied against any party.

 

l.     This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

m.     As used herein, “Dollar”, “US Dollar” and “$” each mean the lawful money of the United States.

 

n.     The parties acknowledge that it would be impossible to fix money damages for violations of this Agreement and that such violations will cause irreparable injury for which an adequate remedy at law is not available. The parties hereby agree that any party hereto may, in its sole discretion, apply to any state or federal court in the State of California for specific performance or similar relief as such court may deem just and proper in order to enforce this Agreement or prevent any violation thereof and, to the extent permitted by applicable law, each party waives any objection or defense to the imposition of such relief. Nothing herein shall be construed to prohibit any party from bringing any action for damages in addition to an action for specific performance or an injunction for a breach of this Agreement.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

16

 

 

IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of the date first written above.

 

	
			 

				
			GIGA-TRONICS INCORPORATED

				
			 

			
	
			 

				
			 

				 	
			 

				
			 

			
	
			 

				
			 

				 	
			 

				
			 

			
	 	 	 	 	 
	
			 

				
			By: 

				 	
			/s/ John Regazzi

				
			 

			
	
			 

				
			Name:

				 	
			 John Regazzi

				
			 

			
	
			 

				
			Title:

				 	
			 Chief Executive Officer

				
			 

			

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

[COUNTERPART SIGNATURE PAGES OF PURCHASER TO FOLLOW]

 

 

 

[Signature Page to Investor Rights Agreement]

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of the date first written above.

 

 

 

PURCHASER:

 

	
			Entity:

				
			Individual:

			
	 	 
	
			___________________________

			 

			 

			 

			By: ________________________

			Name: ______________________

			Title: _______________________

				
			 

			 

			 

			 

			____________________________

			Name: ______________________

			
	 	 
	 	 
	 	 
	
			Number of Preferred Shares subscribed:

				
			_______________

			 

			(Each preferred share originally convertible to 100 shares of common stock)

			
	 	 
	 	 
	 	 
	
			Address for notices:

				 
	 	 
	
			__________________________

			__________________________

			__________________________

			Telephone: ________________

				
			 

			

 

 

 

[Signature Page to Investor Rights Agreement]EX-10.1

 Exhibit 10.1 

Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
 LICENSE
AGREEMENT 
 This License Agreement (“Agreement”) is made as of July 12, 2017 (the “Effective
Date”) by and between BioDelivery Sciences International, Inc., a Delaware corporation with its principal offices at 4131 Parklake Avenue, Suite 225, Raleigh, North Carolina 27612 (“Parent”), its wholly-owned subsidiary
Arius Pharmaceuticals, Inc., a Delaware corporation with an office at the same address (“Arius”, and together with Parent, “BDSI”), and Purdue Pharma, an Ontario limited partnership with its principal office at 575
Granite Court, Pickering, ON Canada L1W 3W8 (“Purdue”). BDSI and Purdue are sometimes referred to collectively herein as the “Parties” or singly as a “Party.” 

RECITALS 
 WHEREAS,
BDSI wishes to grant to Purdue, and Purdue wishes to obtain from BDSI, an exclusive license to develop, manufacture (or have manufactured), market, advertise, promote, distribute, offer for sale, sell, and import the Licensed Product in the
Territory on the terms and subject to the conditions set forth herein. 
 NOW, THEREFORE, in consideration of the foregoing recitals
and the mutual covenants and agreements contained herein, the Parties, intending to be legally bound, do hereby agree as follows: 

ARTICLE I 
 DEFINITIONS

 Section 1.01 Definitions. In addition to the capitalized terms defined elsewhere in this Agreement, the following
terms used in this Agreement shall have the meaning set forth below: 
 “AAA” shall have the meaning set forth in
Section 14.03(c). 
 “Acquired Entity” means, in the event BDSI or any Affiliate thereof acquires any Third Party or
all or substantially all of the stock, assets, or business of a Third Party or otherwise obtains control of a Third Party (with “control”, for purposes of this definition, having the meaning set forth below in the definition of
“Affiliate”), such Third Party or any Affiliate thereof. 
 “Acquiring Entity” means any Third Party that
acquires all or substantially all of the stock, assets, or business of BDSI or any Affiliate thereof (or all or substantially all of the assets or business thereof related, in either case, to this Agreement) or otherwise obtains control of BDSI or
any Affiliate thereof (with “control”, for purposes of this definition, having the meaning set forth below in the definition of “Affiliate”), or any Affiliate of such Third Party. 

“ADE” means any Adverse Event associated with any Licensed Product or Demonstration Sample (including Adverse Drug
Reactions). 

  
 1 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 “Administrative NDS” shall have the meaning set forth in Section 2.01.

 “Adverse BDSI Acquirer” means a Third Party that is marketing, advertising, promoting, offering for sale, or selling, or
has granted exclusive rights to another Third Party to engage in any of the foregoing with respect to, a BDSI Competing Product in the Territory or a Purdue Competing Product in the Territory, provided that marketing, advertising, or promotional
efforts primarily intended for consumption outside the Territory that are nonetheless visible, audible, or otherwise accessible inside the Territory (e.g., via the internet, television or radio broadcast, or the like) shall not themselves be
construed to constitute any of the foregoing activities in the Territory. 
 “Adverse BDSI Acquisition” means the
occurrence of any of the following: (a) any consolidation or merger of Parent with or into any Adverse BDSI Acquirer, or any other corporate reorganization, acquisition or other transaction involving Parent and an Adverse BDSI Acquirer, in
which those persons or entities that are stockholders of Parent immediately prior to such consolidation, merger or reorganization own less than fifty percent (50%) of the surviving entity’s voting power immediately after such consolidation,
merger or reorganization; (b) a change in the legal or beneficial ownership of fifty percent (50%) or more of the voting securities of Parent (whether in a single transaction or series of related transactions) where, immediately after giving
effect to such change, the legal or beneficial owner of more than fifty percent (50%) of the voting securities of Parent is an Adverse BDSI Acquirer; or (c) the sale, transfer, lease, license or other disposition of all or substantially all of
Parent’s assets or business (or that portion thereof related to the subject matter of this Agreement, including the shares or assets of Arius or Arius Two) in one or a series of related transactions to an Adverse BDSI Acquirer. Notwithstanding
the foregoing, an Adverse BDSI Acquisition shall not include a bona fide financing transaction in which voting control of Parent transfers to one or more persons or entities who acquire Parent’s equity securities from Parent in exchange for
either an investment in Parent or the cancellation of indebtedness owed by Parent, or a combination thereof, unless the securities issued to a single Adverse BDSI Acquirer in such financing constitute more than fifty percent (50%) of the voting
securities of Parent outstanding immediately following such financing, in which case such transfer shall be deemed an Adverse BDSI Acquisition. 

“Adverse Event” or “AE” means any untoward medical occurrence in a patient or clinical investigation subject
administered Licensed Products or Demonstration Samples and which does not necessarily have to have a causal relationship with such treatment. 

“Adverse Reaction” or “Adverse Drug Reaction” or “ADR” means a response to any Licensed
Product or Demonstration Sample which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis or therapy of disease or for modification of physiological function. 

“Affiliate” means an individual, trust, business trust, joint venture, partnership, corporation, association or any other
entity which controls, is controlled by or is under common control with, a Party. For the purposes of this definition, the term “control” (including, with correlative meanings, the terms “controlled by” and
“under common control with”) as used with 

  
 2 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
respect to any Party, shall mean the possession (directly or indirectly) of (a) more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a
foreign corporation in a particular jurisdiction) of the outstanding voting securities of a corporation or comparable equity interest in any other type of entity or (b) the power to direct or cause the direction of the management or policies of
any such Party (whether through ownership of securities or other ownership interests, by contract or otherwise). 

“Agreement” shall have the meaning set forth in the introduction. 

“API” means an active pharmaceutical ingredient. 

“Applicable Laws” means all applicable laws, rules, regulations and guidelines that may apply to the development, marketing,
manufacturing or sale of any Licensed Product or the performance of either Party’s obligations under this Agreement, including but not limited to all laws, regulations and guidelines governing the import, export, development, marketing,
distribution and sale of any Licensed Product in the Territory, to the extent relevant, all “current Good Manufacturing Practices” or “current Good Clinical Practices” standards or guidelines promulgated by Governmental
Authorities. 
 “Arius” shall have the meaning set forth in the introduction. 

“Arius Two” shall have the meaning set forth in Section 9.09. 

“Audited Party” shall have the meaning set forth in Section 14.11. 

“BDSI” shall have the meaning set forth in the introduction. 

“BDSI Acquisition” means the occurrence of any of the following: (a) any consolidation or merger of Parent with or into
any Third Party, or any other corporate reorganization, acquisition or other transaction involving a Third Party, in which those persons or entities that are stockholders of Parent immediately prior to such consolidation, merger or reorganization
own less than fifty percent (50%) of the surviving entity’s voting power immediately after such consolidation, merger or reorganization; (b) a change in the legal or beneficial ownership of fifty percent (50%) or more of the voting
securities of Parent (whether in a single transaction or series of related transactions) where, immediately after giving effect to such change, the legal or beneficial owner of more than fifty percent (50%) of the voting securities of Parent is a
Third Party; or (c) the sale, transfer, lease, license or other disposition of all or substantially all of Parent’s assets or business related to the subject matter of this Agreement in one or a series of related transactions to a Third
Party. Notwithstanding the foregoing, a BDSI Acquisition shall not include a bona fide financing transaction in which voting control of Parent transfers to one or more persons or entities who acquire Parent’s equity securities from Parent in
exchange for either an investment in Parent or the cancellation of indebtedness owed by Parent, or a combination thereof, unless the securities issued to a single Third Party in such financing constitute more than fifty percent (50%) of the voting
securities of Parent outstanding immediately following such financing, in which case such transfer shall be deemed a BDSI Acquisition. 

  
 3 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 “BDSI Competing Product” means ***. 

“BDSI Documentation” means all documentation, reports, case report forms, data, information and the like, including all
notes, summaries and analyses related thereto, in whatever form or media, in the possession or control of BDSI or any Affiliate thereof, which result from or otherwise describe (i) pre-clinical, clinical, or other research and development
activities directly related to any Licensed Product, including but not limited to clinical studies or manufacturing- or formulation-related activities, and/or any results thereof, (ii) information directly concerning the use or administration
of Licensed Products, including but not limited to AEs, ADRs, ADEs, and/or SAEs, or (iii) or other BDSI Know-How contained or referenced in any Governmental Approvals or Regulatory Filings. 

“BDSI Improvements” shall have the meaning set forth in Section 3.05. 

“BDSI Indemnitees” shall have the meaning set forth in Section 10.02. 

“BDSI TPMCXA” means: 

(i) for units of Licensed Product supplied by BDSI to Purdue under the Supply Agreement, the total prices paid by BDSI to all
Third Party manufacturers involved in manufacturing a unit of a particular dosage strength of such Licensed Product for such unit supplied to Purdue pursuant to the Supply Agreement (excluding analytical costs for in-process and release testing
performed by such Third Party manufacturers); or 
 (ii) for units of Licensed Product not supplied by BDSI under the Supply
Agreement, Purdue’s reasonable, documented direct cost of procuring such Licensed Product (excluding analytical costs for in-process and release testing performed by such manufacturers). 

“BEMA” means the proprietary bioerodible, mucoadhesive multi-layer polymer film technology Controlled by BDSI, as embodied in
the Current Product as it exists as of the Effective Date, or described in or claimed in any Licensed Patents, and as such may be improved or enhanced by any Licensed Improvement. 

“BEMA-based Product” means any product that incorporates or is based directly on the use of the BEMA technology. 

“Books and Records” means, in whatever media, any and all books and records, reports and accounts directly related to the
Commercialization of the Licensed Product in the Territory or any other activities of the relevant Party (or Affiliate thereof) with respect to Licensed Products. 

“Calendar Quarter” means each of those three (3) calendar month periods of each Calendar Year ending
March 31, June 30, September 30 and December 31, provided, that the initial Calendar Quarter shall begin on the Effective Date and end September 30, 2017. 

  
 4 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 “Calendar Year” means (a) for the first Calendar Year, the period
commencing on the Effective Date and ending on December 31 of the same year, (b) for the Calendar Year in which this Agreement expires or is terminated, the period beginning on January 1 of such Calendar Year and ending on the
effective date of such expiration or termination, and (c) for all other years, each successive twelve (12) consecutive month period beginning on January 1 and ending December 31. 

“CA$” refers to an amount expressed in Canadian dollars. 

“Claims” shall have the meaning set forth in Section 10.01. 

“Commercialization” means the marketing, promotion, advertising, offering for sale, selling and/or distribution of any
Licensed Product; and the term “Commercialize” has a corresponding meaning. 
 “Commercially Reasonable
Efforts” means, with respect to the efforts to be expended by a Party with respect to any objective hereunder, ***. 

“Competent Authorities” means, collectively, the Governmental Authorities in the Territory responsible for the regulation of
medicinal products intended for human use, including Health Canada. 
 “Confidential Information” means all information and
know-how and any tangible embodiments thereof provided by or on behalf of one Party to the other Party or an Affiliate thereof either in connection with the discussions and negotiations pertaining to this Agreement or in the course of performing
under this Agreement, which may include data, knowledge, practices, processes, ideas, research plans, formulation or manufacturing processes and techniques, scientific, manufacturing, marketing and business plans, and financial and personnel matters
relating to the disclosing Party or to its present or future products, sales, suppliers, customers, employees, investors or business; provided, that, information or know-how of a Party will not be deemed Confidential Information of such Party for
purposes of this Agreement if such information or know-how: (a) was already known to the receiving Party, other than under an obligation of confidentiality or non-use, at the time of disclosure to such receiving Party, as can be shown by
written records; (b) was generally available or known to parties reasonably skilled in the field to which such information or know-how pertains, or was otherwise part of the public domain, at the time of its disclosure to such receiving Party;
(c) became generally available or known to parties reasonably skilled in the field to which such information or know-how pertains, or otherwise became part of the public domain, after its disclosure to such receiving Party through no fault of
the receiving Party; (d) was disclosed to such receiving Party, other than under an obligation of confidentiality or non-use, by a Third Party who had no obligation to the disclosing Party not to disclose such information or know-how to others,
as can be shown by written records; or (e) was independently discovered or developed by such receiving Party, as can be shown by its written records, without the use or benefit of, or reliance on, Confidential Information of the disclosing
Party. Notwithstanding anything to the contrary, and regardless of which Party or Affiliate thereof first discloses any information concerning Product Improvements to the other Party or any Affiliate thereof, any information related to Product
Improvements shall be the Confidential Information of BDSI, and BDSI shall be deemed the disclosing Party, and Purdue the receiving Party, with respect to such Confidential Information. 

  
 5 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 “Control” means, with respect to any intellectual property right, regulatory
documentation, clinical data, trademark or trade name, the possession of the ability or right, whether by ownership, license or otherwise, to grant a license or sublicense as provided for herein without violating the terms of any agreement or other
arrangement with any Third Party existing on the Effective Date or, with respect to any intellectual property rights, regulatory documentation, clinical data, trademark or trade name acquired from a Third Party following the Effective Date, any
agreements in effect at the time such rights are acquired or licensed. For Know-How or Patents to which a Party obtains control pursuant to a written agreement executed between such Party or any Affiliate thereof and a Third Party after the
Effective Date, “Control” shall only be deemed to exist pursuant to the first sentence of this definition if the grant of a license or sublicense thereunder, or exercise of rights by the other Party or an Affiliate thereof under such a
license or sublicense, in accordance with this Agreement does not result in such Party or any Affiliate thereof owing payment to a Third Party, unless the other Party agrees to pay the resulting amounts due to the applicable Third Party as a
condition of receiving such grant of rights. 
 “Cover” means that the use, manufacture, sale, offer for sale, development,
commercialization or importation of the subject matter in question by an unlicensed entity would infringe a Valid Claim of a Patent. 

“Current Product” means that certain Licensed Product that is the subject of NDS Dossier ID: 183069 (the “Current
Product NDS”). 
 “Demonstration Samples” means a BEMA-based Product, lacking any API, that otherwise would
constitute a Licensed Product and is used to demonstrate the manner in which a Licensed Product is prepared and used, and labeled “demonstration samples, for demonstration purposes only.” 

“DINs” means the drug identification numbers assigned by Health Canada to the Licensed Product, which are 02465221, 02465248,
02465256, 02465264, 02465272, 02465280, and 02465299. 
 “Effective Date” shall have the meaning set forth in the
introduction. 
 “Endo” means Endo Pharmaceuticals Inc. 

“Endo Health Canada Letter” means the letter from Endo, Paladin, and/or the appropriate affiliate thereof to Health Canada,
duly executed by Endo, Paladin, and/or the appropriate affiliate thereof and in substantially such form as attached hereto as Exhibit F, to be filed with Health Canada, in e-CTD format, to permit Health Canada access to the buprenorphine
(BELBUCA) files in respect of Purdue’s Administrative New Drug Submission for the transfer of the DINs from Paladin to Purdue. 

  
 6 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 “Exchange Rate” means the rate of exchange quoted by the Royal Bank of
Canada on the applicable date as its rate of exchange for converting Canadian dollars into United States dollars. 
 “First
Commercial Sale” means the first sale, or other transfer, exchange, or disposition for value, of a Licensed Product in the Territory by Purdue, an Affiliate thereof, or a Sublicensee following the Effective Date, provided that,
notwithstanding the foregoing, (i) except as set forth in clause (ii) below, a sale in nominal amounts for purposes of ensuring the Licensed Product’s inclusion on a formulary shall not be considered a sale or other transfer,
exchange, or disposition for value for purposes of this definition and, notwithstanding the preceding clause (i), (ii) First Commercial Sale shall in any event be deemed to occur no later than upon CA$*** in gross sales of Licensed Products,
including all such sales in nominal amounts described in clause (i) for purposes of such calculation. 
 “Force
Majeure” shall have the meaning set forth in Section 14.02. 
 “Generic Product” means, with respect to a
Licensed Product, a product sold by a Third Party in the Territory that (a) contains buprenorphine as its sole API, (b) has been declared a bioequivalent of such Licensed Product pursuant to section C.08.004(4) of the Canadian Food and
Drug Regulations or any successor legislation or regulation thereto, as stated on the applicable Notice of Compliance, (c) is approved for use for one or more of the same clinical indications approved for such Licensed Product under an
abbreviated new drug submission submitted pursuant to section C.08.002.1 of the Canadian Food and Drug Regulations or any successor legislation or regulation thereto in which such Licensed Product is the reference listed drug, (d) is
freely substitutable in the provinces of Ontario and Quebec by the pharmacist for such Licensed Product when filling a prescription written for such Licensed Product without having to seek authorization to do so from the physician writing such
prescription, and (e) is not sold pursuant to a sublicense granted under this Agreement to such Third Party by Purdue, its Affiliates, or Sublicensees with respect to such Licensed Product (i.e., is not an “authorized generic”) or any
rights related thereto. 
 “Governmental Approval” means all permits, licenses and authorizations, including but not
limited to, import permits and Marketing Authorizations, required by any Competent Authority as a prerequisite to the manufacturing, marketing, or selling of a Licensed Product for human therapeutic use in the Territory. 

“Governmental Authority” means any domestic or foreign government, whether national, federal, state, provincial, territorial,
local, municipal or other government, any governmental, regulatory or administrative authority, agency or commission, any self-regulatory organization, or any court, tribunal, commission, judicial or arbitral body having adjudicative, regulatory,
judicial, quasi-judicial, administrative or similar functions. 
 “Improvements” means any and all developments,
enhancements, inventions or discoveries directly relating to BEMA, the Licensed Technology, any Licensed Product, or the manufacture or use of any of the foregoing that (i) is invented, conceived, developed or acquired by a Party, any Affiliate
thereof, or any employees, agents, or other representatives of any of the foregoing, solely or jointly with the other Party, any Affiliate thereof, any Third Party, or any 

  
 7 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
employees, agents, or other representatives of any of the foregoing, or (ii) otherwise comes under the Control of a Party or an Affiliate thereof, at any time during the Term, including any
of the foregoing intended to enhance the safety and/or efficacy of a Licensed Product. 
 “Initial BDSI TPMXCA” means, for
each dosage strength of Licensed Product, the BDSI TPMXCA set forth on Exhibit A. 
 “Initial Licensed Patents”
means those Patents set forth on Exhibit C. 
 “Initial NOC Fee Amount” shall have the meaning set forth in
Section 2.01(d). 
 “Joint Improvement” shall have the meaning set forth in Section 3.05. 

“Know-How” means all know-how, trade secrets, inventions, data, processes, techniques, procedures, compositions, devices,
methods, formulas, protocols and information, whether or not patentable, which are not generally publicly known, including, without limitation, all chemical, biochemical, toxicological, and scientific research information, whether in written,
graphic or video form or any other form or format. 
 “Knowledge” of a Party means (a) actual knowledge of any
executive or other senior officer of such Party or Affiliate thereof or (b) any fact or matter known to an employee of such Party or an Affiliate thereof of which any such senior officer of such Party or Affiliate would reasonably be expected
to discover or otherwise become aware of in the course of the reasonable conduct of his or her duties. 
 “Licensed
Improvement” means, to the extent Controlled by BDSI during the Term, (i) any Improvement, including any Joint Improvement, directly concerning Licensed Products (or the manufacture or use thereof) that is invented, conceived, or
developed in whole or in part by BDSI or any of its employees, agents, or other representatives during the Term and (ii) any Product Improvement. 

“Licensed Know-How” means all Know-How that is (a) under the Control of BDSI or any of its Affiliates as of the
Effective Date or comes under BDSI’s or any of its Affiliates’ Control during the Term and (b) necessary or useful to manufacture or Commercialize Licensed Products in the Territory, including any such Know-How concerning Licensed
Improvements, provided that, notwithstanding anything to the contrary, Licensed Know-How shall not include any Know-How that is owned, licensed, or otherwise controlled at any time by any Acquiring Entity or Acquired Entity, except to the extent
such Know-How was already included within the Licensed Know-How immediately prior to the date of the transaction by which such Acquiring Entity or Acquired Entity, respectively, first became an Acquiring Entity or Acquired Entity, respectively. 

“Licensed Marks” means those logos, tradenames, trademarks, and associated registrations or applications therefor in the
Territory set forth on Exhibit B. 
 “Licensed Patents” means, with respect to the Territory, (a) the Initial
Licensed Patents; (b) any additions, divisionals, continuations, continuations-in-part, conversion, supplemental 

  
 8 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
examinations, extensions, term restorations, registrations, re-instatements, amendments, reissuances, corrections, substitutions, re-examinations, revalidations, supplementary protection
certificates, and renewals of the Initial Licensed Patents in the Territory; (c) all patents issuing in the Territory from any of the Patents mentioned in clause (a) or (b) above; and (d) all Patents Controlled by BDSI in the
Territory Covering or otherwise claiming any Licensed Improvement; provided that, notwithstanding anything to the contrary, Licensed Patents shall not include any patents or patent applications that are owned, licensed, or otherwise controlled at
any time by any Acquiring Entity or Acquired Entity, except to the extent that they were already included within the Licensed Patents immediately prior to the date of the transaction by which such Acquiring Entity or Acquired Entity, respectively,
first became an Acquiring Entity or Acquired Entity, respectively. 
 “Licensed Product” means the Current Product or any
other BEMA-based Product which contains buprenorphine as its sole API. 
 “Licensed Technology” means the Licensed Patents
and the Licensed Know-How. 
 “Losses” shall have the meaning set forth in Section 10.01. 

“Marketing Authorization” means all necessary and appropriate regulatory approvals, including variations thereto, to put a
Licensed Product on the market for sale for human therapeutic use in the Territory. 
 “Marketing Authorization Transfer”
means grant of a NOC to Purdue with respect to Licensed Product to transfer the DINs from Paladin to Purdue. 
 “NDS” means
a new drug submission filed pursuant to Section C.08.002 of Canada’s Food and Drugs Regulations, all amendments and supplements thereto, and all additional documentation required to be filed with any Governmental Authority in the Territory for
approval to commence commercial sale of a Licensed Product for human therapeutic use in the Territory. 
 “Negotiation
Notice” shall have the meaning set forth in Section 11.09. 
 “Negotiation Period” shall have the meaning set
forth in Section 11.09. 
 “Net Sales” means ***. 

If any such sales to Third Parties are made in transactions that are not at arm’s length between the buyer and the seller, then the gross
amount to be included in the calculation of Net Sales shall be the amount that would have been invoiced had the transaction been conducted at arm’s length, as reasonably determined in good faith by Purdue, its Affiliate, or Sublicensee, as
applicable, subject to deductions set forth above, and such amount that would have been invoiced shall be determined, wherever possible, by reference to the average selling price of the relevant Licensed Product in arm’s-length transactions in
the Territory. The gross amount of sales to be included in the calculation of Net Sales shall also include the fair market value of any non-cash 

  
 9 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
consideration received by Purdue, its Affiliates or Sublicensees for the sale or other transfers of Licensed Products or any right, title or interest in Licensed Products, subject to the
deductions set forth in clauses (i), (ii), (iii), and (iv) above. Fair market value will be calculated reasonably and in good faith by Purdue as of the time of transfer of such non-cash consideration to Purdue, its Affiliates or Sublicensees.
Net Sales shall be determined, and Books and Records maintained, in accordance with normally accepted accounting principles, such as GAAP, IFRS or similar accounting principles, on a basis consistent with the audited consolidated financial
statements of Purdue, its Affiliates, or its Sublicensees, as applicable. Licensed Products shall be considered sold when billed out or invoiced, or, if not billed out or invoiced, when payment for such Licensed Products is received. 

“NOC” shall have the meaning set forth in Section 2.01. 

“NOC Fees” shall have the meaning set forth in Section 2.01. 

“NOC Filer” shall have the meaning set forth in Section 2.01. 

“On Average” means *** 

“Paid Party” shall have the meaning set forth in Section 4.03(e). 

“Paladin” means Paladin Labs Inc. 

“Parent” shall have the meaning set forth in the introduction. 

“Patents” means all rights under patents and patent applications, and any and all patents issuing therefrom (including
utility, model and design patents, and certificates of invention), together with any and all substitutions, extensions (including supplemental protection certificates), registrations, confirmations, reissues, divisionals, continuations,
continuations-in-part, re-examinations, renewals and domestic and foreign counterparts of the foregoing, and all improvements, supplements, modifications or additions. 

“Paying Party” shall have the meaning set forth in Section 4.03(e). 

“Pharmacovigilance Agreement” shall have the meaning set forth in Section 6.05. 

“Prime Rate of Interest” means the prime rate of interest per annum quoted by the Royal Bank of Canada from time to time as
its reference rate of interest for Canadian Dollar demand loans made to its commercial customers in Canada and which the Royal Bank of Canada refers to as its “prime rate”, as such rate may be changed from time to time. 

“Product Improvement” means any Improvement directly concerning BEMA, any Licensed Product, or the use or manufacture of
either of the foregoing that is invented, conceived, or developed by or on behalf of Purdue, any of its Affiliates, or any of its or their employees, agents, or other representatives, whether alone or jointly with BDSI, any Affiliate thereof, or any
Third Party or any of its or their employees, agents, or other representatives, as a result of the exercise of the rights granted to Purdue with respect to any Licensed Product hereunder or as a result of their access to, or use or knowledge of,
BDSI’s Confidential Information, BEMA, or Licensed Products. 

  
 10 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 “Product Recall” means any recall or market withdrawal of a Licensed Product
from or in the Territory. 
 “Product-Related Contracts” shall have the meaning set forth in Section 13.06. 

“Product-Related Materials” means all advertising and promotional materials (including but not limited to flyers, brochures,
pamphlets and electronic media), labeling and packaging materials, and any materials or items similar to the foregoing to the extent, in each case, pertaining exclusively to the Licensed Products and in the possession or control of Purdue or any
Affiliate thereof, and, to the extent Controlled by Purdue or an Affiliate thereof, all copyright and similar rights to the contents thereof, provided that the foregoing rights shall not include any rights to any trademark, logos, or the like other
than Purdue Marks. 
 “Purdue” shall have the meaning set forth in the introduction. 

“Purdue Competing Product” means ***. 

“Purdue Documentation” means all documentation, reports, case report forms, data, information and the like, including all
notes, summaries and analyses related thereto, in whatever form or media, in the possession or control of Purdue or any Affiliate thereof, which result from or otherwise describe (i) pre-clinical, clinical, or other research and development
activities directly related to any Licensed Product conducted by or for Purdue, its Affiliates, or any Sublicensees in the Territory, including but not limited to clinical studies or manufacturing- or formulation-related activities, and/or any
results thereof, (ii) information obtained by or on behalf of Purdue or Affiliate thereof directly concerning the use or administration of Licensed Products, including but not limited to AEs, ADRs, ADEs, and/or SAEs, or (iii) or other
Purdue Know-How contained or referenced in any Governmental Approvals or Regulatory Filings, excluding for greater certainty any Purdue information not related to the Licensed Product or its Commercialization, use, or manufacture. 

“Purdue Improvement” shall have the meaning set forth in Section 3.05. 

“Purdue Indemnitees” shall have the meaning set forth in Section 10.01. 

“Purdue Know-How” means any Know-How generated by or on behalf of Purdue or any Affiliate thereof during the Term, or that
otherwise comes under the Control of Purdue or any Affiliate thereof following the Effective Date and during the Term, that results from, or directly and solely relates to, the manufacture or Commercialization of, or exercise of any rights granted
under this Agreement with respect to, any Licensed Product by or on behalf of Purdue, its Affiliates, or any Sublicensees, as applicable, or Purdue’s, its Affiliates’, or Sublicensees’ access to, or use or knowledge of, BDSI’s
Confidential Information or BEMA, as applicable, including any Know-How coming under the Control of Purdue or its Affiliates relating to any Purdue Improvement. 

  
 11 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 “Purdue Marks” means any trademarks, service marks, trade dress, or logos
under Control of Purdue or any Affiliate thereof that are used by Purdue, any Affiliate thereof, or any Sublicensee specifically for any Licensed Product at any time in connection with the use, development, promotion, marketing, distribution, offer
for sale, or sale of any Licensed Product in the Territory, other than (a) the Licensed Marks and (b) any trademarks, trade names, service marks, trade dress, or logos that are generally representative of Purdue, any Affiliate thereof, or
any Sublicensee as a business or any products of any of the foregoing other than any Licensed Products. 
 “Purdue Patents”
means any Patents under the Control of Purdue or any Affiliate thereof during the Term that Cover any Purdue Know-How or any Purdue Improvement. 

“Quality Agreement” shall have the meaning set forth in Section 6.05. 

“Reasonable Cross Border Efforts” means ***. 

“Regulatory Filing” means an application for Marketing Authorization, investigational new drug application, clinical trial
applications, preclinical and clinical studies and tests related to the Licensed Product, any drug master files or the like in the Territory, and any other filings or submissions required by or provided to Competent Authorities relating to the
research, development, use, manufacture, or Commercialization of any Licensed Product, including any supporting documentation, correspondence, meeting minutes, amendments, supplements, registrations, governmental licenses or permits, regulatory drug
lists, advertising and promotion documents, adverse event files, complaint files, and manufacturing, shipping, or storage records with respect to any of the foregoing. 

“Requesting Party” shall have the meaning set forth in Section 14.11. 

“ROFN Notice” shall have the meaning set forth in Section 11.09. 

“ROFN Notice Period” shall have the meaning set forth in Section 11.09. 

“ROFN Product” means ***. 

“ROFR Patents” shall have the meaning set forth in Section 11.10. 

“ROFR Product” means ***. 

“ROFR Product License Agreement” shall have the meaning set forth in Section 11.10. 

“Royalty Statement” shall have the meaning set forth in Section 4.03(a). 

“Rules” shall have the meaning set forth in Section 14.03(c). 

“Sensitive Information” shall have the meaning set forth in Section 5.02. 

  
 12 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 “Serious Adverse Event” or “SAE” means an Adverse Event
that at any dose (a) results in death, (b) is life-threatening, (c) requires inpatient hospitalization or prolongation of existing hospitalization, (d) results in persistent or significant disability/incapacity, or
(e) results in a congenital anomaly/birth defect. The term “life-threatening” in this definition refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically
might have caused death if it had been more severe. Important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or require intervention to prevent one of the other
outcomes listed above should also be included in this definition to the extent reasonable medical and scientific judgement indicates that expedited reporting is appropriate under Applicable Laws. 

“Serious Adverse Reaction” or “SAR” means an Adverse Reaction that at any dose (a) results in death,
(b) is life-threatening, (c) requires inpatient hospitalization or prolongation of existing hospitalization, (d) results in persistent or significant disability/incapacity, or (e) results in a congenital anomaly/birth defect. The
term “life-threatening” in this definition refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it had been more severe.
Important medical events that may not immediately result in death or hospitalization but may jeopardize the patient or require intervention to prevent one of the other outcomes listed above should also be included in this definition to the extent
reasonable medical and scientific judgement indicates that expedited reporting is appropriate under Applicable Laws. 

“Sublicensee” means any Third Party, other than an Affiliate of Purdue, to whom any of the rights granted to Purdue under
this Agreement have been sublicensed as permitted hereby. 
 “Supply Agreement” means that certain Supply Agreement between
Parent and Purdue dated as of the Effective Date. 
 “Term” shall have the meaning set forth in Section 13.01. 

“Territory” means Canada. 

“Third Party” means any entity other than: (a) BDSI, (b) Purdue, or (c) an Affiliate of BDSI or Purdue. 

“Third Party Claim” shall have the meaning set forth in Section 7.04. 

“Third Party License” shall have the meaning set forth in Section 11.10. 

“Third Party Offer” shall have the meaning set forth in Section 11.10. 

“Valid Claim” means a claim of any pending Patent application or issued and unexpired Patent that has not been disclaimed,
revoked, held unenforceable, unpatentable or invalid by a decision of a court or other Governmental Authority of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and that has not been admitted to be invalid or
unenforceable through re-examination, re-issue, disclaimer or otherwise, or lost in an interference proceeding. 

  
 13 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 Section 1.02 Interpretation. The Section headings contained in this
Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement. Except where the context clearly requires to the contrary: (a) each reference in this Agreement to a designated “Section”
or “Exhibit” is to the corresponding Section or Exhibit of or to this Agreement; (b) instances of gender or entity-specific usage (e.g., “his” “her” “its” “person” or “individual”)
shall not be interpreted to preclude the application of any provision of this Agreement to any individual or entity; (c) “including” shall mean “including, without limitation”; (d) references to Applicable Laws shall
mean such Applicable Laws in effect during the Term (taking into account any amendments thereto effective at such time without regard to whether such amendments were enacted or adopted after the Effective Date); (e) references to
“CA$”, “$” or “dollars” shall mean the lawful currency of Canada unless otherwise explicitly indicated, on a case-by-case basis to refer to the lawful currency of the United States; (f) references to
“Federal” or “federal” shall be to laws, agencies or other attributes of the United States (and not to any State or locality thereof); (g) the meaning of the terms “domestic” and “foreign” shall be
determined by reference to the United States; (h) references to “days” shall mean calendar days; (i) references to months or years shall be to the actual calendar months or years at issue (taking into account the actual number of
days in any such month or year); and (j) days, business days and times of day shall be determined by reference to Raleigh, North Carolina. 

ARTICLE II 
 INITIAL
APPROVAL 
 Section 2.01 Initial Marketing Authorization. 

(a) The Parties acknowledge that a notice of compliance (“NOC”) with respect to the Current Product NDS was
issued to Paladin (the “NOC Filer”) on June 21, 2017. 
 (b) BDSI shall use its best efforts to cause
a transfer of such Marketing Authorization in the Territory to Purdue as soon as reasonably possible following the Effective Date, including, within *** business days of the Effective Date, causing the NOC Filer to submit the Endo Health Canada
Letter to Health Canada. BDSI shall notify Purdue of any correspondence it receives with respect to the Current Product NDS within *** business days following its receipt by BDSI. BDSI acknowledges and agrees that, subject to Section 2.01(d),
BDSI shall be responsible for all costs and expenses it incurs in connection with its performance of its obligations under this Section 2.01. 

(c) Purdue shall use its best efforts to file, with the Competent Authority, an administrative new drug submission for the
Licensed Product (an “Administrative NDS”) to transfer from the NOC Filer to Purdue the DINs as soon as reasonably possible after 

  
 14 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
the NOC Filer’s submission of the Endo Health Canada Letter to Health Canada, and in any case within *** days after the labeling information required to complete the Administrative NDS is
prepared and approved by Purdue and BDSI, such approval in either case not to be unreasonably withheld, and Purdue shall thereafter use its best efforts to cause, as soon as reasonably possible, the grant of a NOC, and transfer and re-assignment of
the DINs, to Purdue. BDSI shall use (i) its best efforts to cause the NOC Filer to take all reasonable actions necessary to initiate the transfer of the DINs to Purdue, including causing the NOC Filer to provide a letter to the Competent
Authority in the appropriate form authorizing the Competent Authority to transfer the DINs issued to the NOC Filer, with such transfer to take effect as soon as reasonably possible thereafter and (ii) Commercially Reasonable Efforts to provide
reasonable assistance to Purdue to file at the Competent Authority its Administrative NDS. 
 (d) Purdue shall reimburse
BDSI ***. 
 (e) In the event any Governmental Authority in the Territory explicitly requires, as evidenced by written
communication therefrom, ***. 
 Section 2.02 Purdue Development. Except in accordance with Section 2.01(e), Purdue
shall use Commercially Reasonable Efforts to comply with and, upon Marketing Authorization Transfer, maintain all Governmental Approvals in the Territory. Except as may explicitly be provided in the Supply Agreement, BDSI will have the right to
review and comment, and have such comments reasonably considered by Purdue, reasonably in advance with regard to all development-, manufacturing- and formulation-related activities proposed to be conducted by or on behalf of Purdue or any Affiliate
thereof in regards to any Licensed Product in the Territory. In addition, except as explicitly permitted by the Supply Agreement, Purdue shall not, without BDSI’s consent, develop, Commercialize, undertake any dosage-, manufacturing-, or
formulation-related changes to the Current Product or any other Licensed Product. Notwithstanding the foregoing, it is hereby acknowledged by BDSI that no such development- or formulation-related activities, including clinical studies, are planned
or contemplated by Purdue as of the Effective Date. 
 Section 2.03 Regulatory Submissions. At all times, the Party
preparing, filing, and/or maintaining applications for Governmental Approval, or any supplements thereto, in the Territory shall (a) inform the other Party of all material communications with the relevant Competent Authority(ies) concerning the
Licensed Product and (b) provide copies of proposed material submissions to the relevant Competent Authority(ies) concerning the Licensed Product to the other Party prior to their submission to such Competent Authority. To the extent either
Party receives material written or material oral communication from any Governmental Authority in the Territory with respect to any Licensed Product, the Party receiving such communication shall promptly notify the other Party and provide a copy of
any written communication as soon as reasonably practicable. Except as expressly set forth in Section 2.01(c), each Party will be responsible for its own costs and expenses incurred in connection with its performance of the activities set forth
in this Section 2.03. 

  
 15 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 Section 2.04 Reporting. Once per Calendar Quarter and at such other times
as may be reasonably requested by Purdue, BDSI shall provide Purdue with summary updates regarding the progress of its activities with respect to its obligations under this Article II, provided that BDSI’s obligations under this sentence shall
terminate upon Marketing Authorization Transfer. During the first four (4) complete Calendar Quarters following the Effective Date, Purdue shall: (a) provide to BDSI its reasonably detailed commercial launch plan for the Licensed Products
in the Territory (to be provided in or about ***) and (b) upon BDSI’s request, from time-to-time, BDSI shall have reasonable opportunities to discuss any of the foregoing or its other Commercialization plans and efforts with Purdue, which
opportunities shall include, but not be limited to, two teleconferences, each to occur in separate Calendar Quarters of BDSI’s choosing, at such dates and times as the Parties shall reasonably agree in good faith. Without limiting the foregoing
and in conformity with standard pharmaceutical industry practices and the terms and conditions of this Agreement, Purdue shall maintain complete and accurate Books and Records of its and its Affiliates’ research, development, manufacture, and
Commercialization of the Licensed Products for a minimum of *** years following the end of the Calendar Year to which they pertain. 

Section 2.05 Ownership of Regulatory Documentation. Subject to the terms of this Agreement, including Sections 3.06 and
13.06, and without affecting ownership or title to any BDSI Know-How or BDSI Documentation contained or referenced therein, Purdue shall, following the Marketing Authorization Transfer, own all Marketing Authorizations, Governmental Approvals and
all other Regulatory Filings related thereto in the Territory with respect to Licensed Product, except those filings that may be made by or on behalf of BDSI, any Affiliate thereof, or any Third Party in relation to the exercise of BDSI’s
retained rights with respect to Licensed Products in the Territory or performance of BDSI’s obligations under this Agreement or the Supply Agreement. 

ARTICLE III 
 LICENSES;
IMPROVEMENTS 
 Section 3.01 License Fee. In partial consideration for the licenses granted under
Section 3.02(a), Purdue shall pay to BDSI an initial one-time non-refundable license fee of ***, by wire transfer of immediately available funds to an account to be designated by BDSI. Purdue shall pay such license fee within *** days of the
Effective Date. 
 Section 3.02 Licensed Technology. The terms and conditions of the license granted to Purdue shall be
as follows: 
 (a) Subject to the terms and conditions of this Agreement, BDSI hereby grants to Purdue an exclusive (subject to BDSI’s
retained rights under this Section 3.02(a)), royalty-bearing, license under the Licensed Technology to manufacture or have manufactured (subject to the terms of the Supply Agreement), import, and Commercialize the Licensed Product(s) in the
Territory, which license shall be sublicensable as set forth in the second paragraph of this clause (a). Notwithstanding anything to the contrary (including but not limited to the exclusivity of the rights granted above or below), BDSI retains, on
behalf of it, its Affiliates, and its or their 

  
 16 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
contractors, licensees, or sublicensees, sublicensable rights, transferable in accordance with Section 14.01, under the Licensed Technology and Licensed Marks to (i) perform BDSI’s
obligations under Article II and such other obligations as are necessary to reflect the NOC Filer’s status as the initial holder of the Current Product NDS, but only during the period from the Effective Date until the Marketing Authorization
Transfer, and (ii) research, develop, manufacture, have manufactured, use or import Licensed Products or Demonstration Samples in the Territory but solely for purposes related to the export, distribution, use, development, or commercialization
thereof outside the Territory. For clarity, BDSI’s or its Affiliates’ purchase of Licensed Products or Demonstration Samples in the Territory and its or their subsequent sale and export of such Licensed Products or Demonstration Samples to
BDSI’s Affiliates or Third Parties located outside of the Territory for purposes of enabling the sale and/or use of such products outside the Territory are included within the scope of BDSI’s retained rights set forth in clause
(ii) above. Once per Calendar Quarter and at such other times as may be reasonably requested by Purdue, BDSI shall provide Purdue with summary updates regarding its research, development or manufacturing activities (whether directly or through
a Third Party) in respect of the Licensed Products or Demonstration Samples in the Territory if BDSI undertakes any such activities as allowed under this Section 3.02(a). 

Purdue shall have the right to sublicense any rights granted to it under this clause (a) or Section 3.03(a) within the Territory,
provided that (i) Purdue shall provide BDSI with a copy of any executed sublicense agreement (subject to the last sentence of this Section 3.02(a)), (ii) Purdue shall not grant any Affiliate or Third Party any rights to Commercialize
any Licensed Products, nor utilize any Third Party, other than employees of Purdue, to Commercialize any Licensed Products unless, in any of the foregoing cases, consented to in writing by BDSI, such consent not to be unreasonably withheld, provided
that the foregoing shall not be construed to prohibit any assignment of this Agreement by Purdue pursuant to Section 14.01, (iii) Purdue shall secure all reasonably appropriate covenants, obligations and rights from each Sublicensee to
ensure that Purdue can comply with its obligations under this Agreement, (iv) Purdue shall be responsible and liable for each Sublicensee’s performance of Purdue’s obligations hereunder and compliance with the terms of this Agreement,
(v) all Sublicensees shall agree to be subject to the terms of this Agreement, and (vi) all sublicenses shall terminate upon the expiration or termination of this Agreement. The copy of any executed sublicense agreement provided by Purdue
to BDSI pursuant to this paragraph shall be redacted as determined by Purdue, in good faith, to be necessary to protect any of its or its Sublicensee’s confidential or proprietary information unrelated to Purdue’s compliance with its
obligations to BDSI hereunder. 
 (b) Purdue acknowledges that it shall have no right, title or interest in or to the Licensed Technology,
Licensed Products, or Licensed Marks except to the extent set forth in this Agreement, and BDSI reserves all rights to make, have made, use, sell, offer for sale, and import the Licensed Technology and Licensed Products except as otherwise expressly
granted to Purdue pursuant to this Agreement. Nothing in this Agreement shall be construed to grant Purdue any rights or license to any intellectual property of BDSI or any Affiliate thereof other than as expressly set forth herein and nothing in
this Agreement shall be construed to grant BDSI any rights or license to any intellectual property of Purdue or any Affiliate thereof other than as expressly set forth herein. 

  
 17 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 (c) Purdue shall be fully responsible and liable for the acts and omissions of its Affiliates
in the course of any such Affiliate exercising any rights granted, or performing any obligations of Purdue, under this Agreement as if such acts or omissions had been those of Purdue, including but not limited to any breach of the provisions of this
Agreement in connection therewith, and Purdue shall ensure that (i) all Affiliates of Purdue granted rights, performing obligations hereunder, or exercising rights hereunder (“Purdue Affiliates”) shall comply with the terms of
this Agreement and (ii) no Affiliates other than Purdue Affiliates obtain access to, or know or use, BDSI’s Confidential Information, BEMA, or any Licensed Product. BDSI shall be fully responsible and liable for the acts and omissions of
its Affiliates in the course of any such Affiliate exercising any rights granted, or performing any obligations of BDSI, under this Agreement as if such acts or omissions had been those of BDSI, including but not limited to any breach of the
provisions of this Agreement in connection therewith, and BDSI shall ensure that all BDSI Affiliates granted rights, performing obligations hereunder, or exercising rights granted hereunder (“BDSI Affiliates”) shall comply with the
terms of this Agreement. 
 (d) BDSI shall, upon reasonable request of Purdue, use Commercially Reasonable Efforts to promptly provide
Purdue with copies of any BDSI Documentation, Licensed Know-How (to the extent material and in written form), or Licensed Patents, to the extent not prohibited by Applicable Law, not previously provided to Purdue, and Purdue has been granted rights
thereto pursuant to this Agreement, provided that the foregoing obligation shall only apply with respect to any manufacturing-related Licensed Know-How to the extent (i) necessary to enable Purdue to satisfy any requirements under Applicable
Law or (ii) requested upon a Supply Deficiency (as defined in the Supply Agreement) or Supply Failure (as defined in the Supply Agreement) and necessary to enable Purdue to manufacture or have manufactured (by Third Parties) Licensed Products
as permitted by Sections 4.10 or 4.11 of the Supply Agreement or following termination thereof. 
 Section 3.03 Licensed
Marks. 
 (a) License. Subject to the terms and conditions of this Agreement and BDSI’s exercise of its retained
rights under Section 3.02 (with respect to which BDSI, its Affiliates, and Third Parties shall be entitled to use the Licensed Marks), BDSI hereby grants to Purdue an exclusive, paid-up, sub-licensable (subject to the constraints on
sublicensing described in Section 3.02 above), royalty-free license in the Territory to use the Licensed Marks during the Term solely in connection with the manufacture and/or Commercialization of the Licensed Products in the Territory. Purdue
acknowledges that it shall have no right, title or interest in or to the Licensed Marks except to the extent set forth in the license granted to Purdue under this Section 3.03, and BDSI reserves all rights to use the Licensed Marks other than
those rights granted herein. Notwithstanding anything to the contrary, Purdue shall be entitled to use any trademark other than the Licensed Marks, together with the Licensed Marks or otherwise, in connection with the manufacture and/or
Commercialization of the Licensed Products in the Territory. 

  
 18 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 (b) Use of Licensed Marks. Purdue shall comply in all material respects
with all Applicable Laws pertaining to the proper use and designation of the Licensed Marks. Additionally, Purdue shall: 

(i) ensure that the Licensed Marks are accompanied by words accurately describing the nature of the goods or services to which
it relates and that the Licensed Marks are displayed as set forth in Exhibit D; 
 (ii) to the extent reasonably
practicable after receipt of a written request from BDSI, comply with the reasonable requirements of BDSI as to the form, manner, scale and context of use of the Licensed Marks, the use of the statements to accompany them, as well as the appearance
of the Licensed Marks on containers, packaging and related marketing and promotional materials to be used for Licensed Product; 

(iii) display the proper form of trademark and service mark notice associated with each Licensed Mark in accordance with
instructions received from BDSI; 
 (iv) include, on any item which bears a Licensed Mark, a statement identifying BDSI as
the owner of such Licensed Mark and stating that Purdue is an authorized user of such Licensed Mark; 
 (v) not conduct,
without the written consent of BDSI, the whole or any part of its business under a business name or trading style which incorporates any of the Licensed Marks; 

(vi) neither use nor display any of the Licensed Marks in such relation to any other mark or marks owned by any Third Party,
Purdue, or an Affiliate of Purdue as to suggest that the multiple marks constitute a single or composite trademark, service mark, or are under the same proprietorship; and 

(vii) ensure the Licensed Marks are only used with Licensed Products that are used or Commercialized in compliance with
Applicable Laws and Governmental Approvals therefor. 
 (c) Additional Terms. Purdue shall not take any action
inconsistent with BDSI’s ownership of the Licensed Marks. Any benefits (including goodwill) accruing from Purdue’s use of the Licensed Marks shall automatically vest in BDSI. Purdue shall not form any combination trademarks or trade names
with the Licensed Marks. Purdue shall grant BDSI reasonable access to Purdue’s and its Affiliates’ facilities, labeling, packaging and promotional materials for the purpose of inspecting the use of the Licensed Marks pursuant to this
Agreement in accordance with Section 14.11. 
 (d) Termination of License. BDSI shall be entitled to terminate the
rights to Licensed Marks granted above on written notice to Purdue if, after the date of First Commercial Sale, Purdue does not use the Licensed Marks with respect to the Licensed Product for any consecutive period of twelve (12) months or
more, unless the failure to use the Licensed Marks by Purdue is due to a failure or delay by BDSI in the performance of its obligations under this Agreement or the Supply Agreement, in which case the period described herein shall be extended by the
duration of such failure or delay by BDSI. 

  
 19 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 Section 3.04 Limitations Prior to Marketing Authorization Transfer.
Purdue shall ensure that neither Purdue, any Affiliate thereof, nor any Third Party acting on behalf of either of the foregoing shall engage in any activity with respect to Licensed Products prior to Marketing Authorization Transfer except as
permitted by this Agreement and except as may be performed in accordance with Applicable Law by a party that does not hold the Marketing Authorization for any Licensed Products in the Territory, provided that Purdue shall provide BDSI with prior
written notice describing in reasonable detail any proposed such activity and, unless (x) BDSI reasonably determines in good faith that such proposed activity has a material likelihood of adversely effecting (i) the status of the Current
Marketing Authorization or (ii) the Commercialization of Licensed Products in the Territory and (y) BDSI provides notice of such determination to Purdue within *** days of BDSI’s receipt of the above-referenced notice from Purdue
describing such proposed activity, Purdue shall be free to engage in such activity, subject to the terms of this Agreement. 

Section 3.05 Ownership of Improvements. Each Party will own all right, title and interest in and to any Improvements
conceived, developed, invented or otherwise generated solely by such Party, its Affiliates, or any officer, director, employee, agent, or other representative of either of the foregoing, other than Product Improvements, and all intellectual property
rights related thereto (such Improvements and intellectual property rights related thereto to be owned solely by Purdue or any Affiliate thereof pursuant to the foregoing, “Purdue Improvements”, and such Improvements and
intellectual property rights related thereto to be owned solely by BDSI or any Affiliate thereof pursuant to the foregoing, “BDSI Improvements”), and the Parties shall jointly own all right, title, and interest in and to any
Improvements conceived, developed, invented or otherwise generated jointly by (a) BDSI, any Affiliate thereof, or any officer, director, employee, agent, or other representative of either of the foregoing and (b) Purdue, any Affiliate
thereof, or any officer, director, employee, agent, or other representative of either of the foregoing, other than Product Improvements, and all intellectual property rights related thereto (such Improvements and intellectual property rights to be
owned jointly by the Parties pursuant to the foregoing, “Joint Improvements”), provided that, notwithstanding anything to the contrary, Parent shall own, and Purdue shall assign, and hereby assigns, to Parent all right, title, and
interest in and to any Product Improvements and all intellectual property rights related thereto, free and clear of all liens, claims, and encumbrances not set forth in this Agreement. Except as expressly provided in this Agreement and subject to
any restrictions herein, each joint owner of a Joint Improvement may make, sell, use, license, assign, mortgage or keep Joint Improvements, and otherwise undertake all activities a sole owner might undertake with respect to such inventions,
discoveries and know-how, without the consent of and without accounting to the other joint owner, provided that any assignment, license or other disposition or use (i) shall at all times be and remain subject to the grants of rights and
licenses and accompanying conditions and obligations with respect thereto under this Agreement, including under Sections 3.02(a), 3.06 and 13.06(a), and (ii) allow the Parties to exercise their rights and perform their obligations under this
Agreement, in particular to develop, manufacture, and commercialize Licensed Products in at least the same scope as prior to such assignment, license or other such disposition. Each Party shall take all actions and execute all documents necessary to
effect the purposes of the foregoing, as reasonably requested by, and at the sole expense (which shall be reasonable and documented) of, the other Party, and cause its 

  
 20 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
respective Affiliates, and its and their officers, directors, employees, agents, representatives, contractors, and other representatives to do the same. During the Term, each Party shall promptly
notify the other Party in writing and in reasonable detail of any Improvements generated or Controlled by such Party or any Affiliate thereof to which the other Party has any rights under this Agreement. 

Section 3.06 Licenses to BDSI. Purdue hereby grants to BDSI an exclusive, royalty-free, fully-paid, freely sublicensable,
worldwide, perpetual, irrevocable, exclusive license and right of reference, transferable with this Agreement in accordance with Section 14.01, (X) under the Purdue Documentation (to the extent Controlled by Purdue or its Affiliates),
Governmental Approvals, Regulatory Filings, and, to the extent contained or referenced in any of the foregoing, Purdue Know-How, in each case solely to extent needed for BDSI, any Affiliate thereof, any licensee or sublicensee of either of the
foregoing, or any contractor of any of the foregoing to comply with any applicable law, rule, regulation, or guideline or order or request of any Governmental Authority with respect to any BEMA-based Products other than Licensed Products and
(Y) under the Purdue Improvements (and any related Purdue Know-How and Purdue Patents), Purdue’s and its Affiliates’ rights in any Joint Improvements (and any related Purdue Know-How and Purdue Patents), Purdue Documentation (to the
extent Controlled by Purdue or its Affiliates), Governmental Approvals, Regulatory Filings, and, to the extent contained or referenced in any of the foregoing, Purdue Know-How to (1) make, have made, use, import, research, and develop Licensed
Products and Demonstration Samples anywhere in the world and (2) sell, offer for sale, and otherwise commercialize Licensed Products and Demonstration Samples outside the Territory and, upon expiration or termination of this Agreement, inside
the Territory, provided that the license granted under this clause (Y) with respect to Purdue Improvements directly and solely concerning buprenorphine shall only include rights to such Purdue Improvements to the extent solely related to
Licensed Products, BEMA, or any Licensed Technology. Purdue shall, upon reasonable request of BDSI, promptly provide BDSI with copies of any Purdue Documentation, Purdue Know-How, Purdue Patents, or other Patents Covering any Purdue Improvements or
Joint Improvements to the extent not prohibited by Applicable Law, not previously provided to BDSI, and BDSI has been granted rights thereto pursuant to this Agreement. 

ARTICLE IV 
 ROYALTY AND
MILESTONE PAYMENTS 
 Section 4.01 Royalty Payments. 

(a) Base Royalty. Except as otherwise set forth in this Agreement, Purdue will make quarterly royalty payments to BDSI equaling *** of
Net Sales. 
 (b) ***. 
 (c)
Adjustment Upon Generic Competition. If, for any Calendar Quarter during the Term, total sales of Generic Product (in units) in the Territory equals or exceeds *** of total combined sales (in units) of Licensed Products and Generic Products
in the Territory, the royalty rate set out in Section 4.01(a), as it may be adjusted by Section 4.01(b), applicable to Net Sales during such Calendar Quarter shall be reduced by ***. 

  
 21 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 (d) Minimum Royalties. Within *** days following the *** anniversary of the First
Commercial Sale and each anniversary thereof thereafter during the Term, Purdue shall pay BDSI an annual fee of CA$***, which amount shall be creditable against royalties due under Section 4.01(a), as adjusted pursuant to Sections 4.01(b) and
4.01(c), for the four (4) complete Calendar Quarters following the Calendar Quarter during which such anniversary occurs, provided that, notwithstanding the foregoing, (i) Purdue shall not be obligated to make any payments under this
Section 4.01(d) if, at the time any such payment is due, a Generic Product has obtained Governmental Approval from the applicable Regulatory Authority in the Territory and been commercially sold by a Third Party in the Territory and
(ii) ***. 
 Section 4.02 Milestone Payments. Purdue shall pay to BDSI, as additional license fees, the following
non-refundable, non-creditable milestone payments upon the occurrence of the specified milestone event: 
 (a) CA$*** upon
Marketing Authorization Transfer; 
 (b) CA$*** upon First Commercial Sale of any Licensed Product; 

(c) an amount equal to the applicable Milestone Payment set forth on Exhibit E when Annual Net Sales first exceed
CA$***; and 
 (d) an amount equal to the applicable Milestone Payment set forth on Exhibit E upon the *** of First
Commercial Sale, provided that, if a Generic Product has been approved and commercially sold in the Territory by a Third Party prior to such anniversary, no amount shall be due under this clause (d). 

For the avoidance of doubt, each milestone payment referred to in this Section 4.02 shall be paid only once by Purdue, the first time the
relevant milestone is achieved. Purdue shall provide BDSI written notice of the achievement of each milestone specified above, and Purdue shall pay BDSI the designated amount for such milestone, within *** days of such achievement. 

Section 4.03 Reports and Payments. 

(a) Purdue, on behalf of itself and its Affiliates, shall, beginning with the initial Calendar Quarter during which Net Sales first occur,
furnish to BDSI a quarterly written report (each, a “Royalty Statement”) showing in reasonably specific detail (i) Purdue’s, its Affiliates’, and Sublicensees’ inventory on hand of each stock keeping unit
(“SKU”) of Licensed Products, sales of Licensed Products per SKU and Net Sales per SKU; (ii) amounts payable under this Agreement based upon such Net Sales (which shall include a detailed accounting of all amounts and
calculations required to determine Net Sales and the amounts payable under this Agreement consistent with Sections 4.01 and 4.02); (iii) withholding taxes, if any, required by Applicable Law to be deducted with respect to any payments due BDSI
under this Agreement; and (v) the date of the first commercial sale of any Licensed Product in the Territory during the reporting period. Royalty Statements shall be due no later than *** days following the close of each Calendar Quarter. 

  
 22 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 (b) All payments due BDSI under Section 4.01 with respect to a particular Calendar
Quarter shall be due no later than *** days following the end of each Calendar Quarter. All payments hereunder shall be made in United States dollars. Currency conversion for determining amounts payable in United States dollars shall be made at the
Exchange Rate applicable on (i) the last business day of the applicable Calendar Quarter (for payments due under Section 4.01 or otherwise made on a Calendar Quarterly basis), (ii) the business day on which the applicable payment is
triggered (or, if not triggered on a business day, the nearest business day preceding such date) (for payments due under Section 4.02 or any other payments triggered on a specific date), or (iii) for any other payments not covered by the
preceding clause (i) or (ii), the last business day of the calendar month preceding the calendar month in which such payment is made. All payments owed under this Agreement shall be made by wire transfer to one or more bank accounts (which may
each be the account of such Party, any Affiliate thereof, or any Third Party), in such allocation between such accounts, as shall be designated by the Party owed payment from time-to-time upon written notice, unless otherwise specified in writing by
such Party, with any such designated account(s) and/or allocation(s) to remain effective with respect to payments owed to such Party until it provides written notice to the other Party setting forth any changes to such account(s) or allocation(s)
for payment (in which case any changes specified in such notice shall become effective on the date specified therein). 
 (c) In the event
that any payment due hereunder is not made when due, such payment shall accrue interest from the date due at a rate equal to the greater of (i) the Prime Rate of Interest plus *** or (ii) *** per month, or, if less, the maximum interest
rate legally permissible in the Territory, calculated based on the number of days such payments are paid after the date such payments are due. The payment of such interest shall not limit a Party from exercising any other rights it may have under
this Agreement as a consequence of the lateness of any payment. 
 (d) During the Term and for a period of *** thereafter, or longer if and
as required in order for Purdue to comply with Applicable Law, Purdue shall keep complete and accurate records in sufficient detail to permit BDSI to confirm the completeness and accuracy of (i) the information presented in each Royalty
Statement and all payments due hereunder and (ii) the calculation of Net Sales. BDSI and any designee thereof shall have the right to audit and inspect such Books and Records pursuant to the terms of Section 14.11 solely to confirm
completeness and accuracy of the information in the Royalty Statements and amounts of payments due under this Article IV. 
 (e) All taxes
levied on account of the payments accruing to a Party under this Agreement shall be paid by such Party for its own account, including taxes levied thereon as income to such Party. If provision is made in Applicable Law for withholding, such tax
shall be deducted from the payment made by a Party (the “Paying Party”) to the other Party (the “Paid Party”) hereunder, shall be paid to the proper taxing authority by the Paying Party, and a receipt of payment of
such tax shall be secured and promptly delivered to the Paid Party. Each Party agrees to reasonably assist the other Party, as reasonably requested thereby and at the Paid Party’s expense, in claiming exemption from such deductions or
withholdings under any double taxation or similar agreement or treaty from time to time in force or in otherwise seeking the return, refund, or credit of any such withheld amount as applicable. 

  
 23 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 ARTICLE V 

COMMERCIALIZATION 

Section 5.01 Commercialization Obligations. 

(a) Purdue shall use Commercially Reasonable Efforts to cause the First Commercial Sale of Licensed Product to occur as soon as reasonably
practicable following Marketing Authorization Transfer, subject to, without limitation, BDSI’s ability to supply Licensed Product in a timely manner therefor under the Supply Agreement, and Purdue shall use Commercially Reasonable Efforts to
Commercialize Licensed Products in the Territory, *** and (ii) a Commercially Reasonable initial commercial and promotional launch of the Licensed Product and post-launch marketing and promotion thereof. As between the Parties, Purdue, at its
own expense, will be responsible for all of its Commercialization activities in the Territory. Except as otherwise explicitly provided in this Agreement, and without limitation of Purdue’s obligations above under this Section 5.01(a),
Purdue shall determine, in its sole discretion, all aspects of the Commercialization activities and be responsible for market access for Licensed Products in the Territory. 

(b) Purdue shall determine pricing for Licensed Products in the Territory in its sole discretion. Purdue will not, and will ensure that its
Affiliates and Sublicensees do not, ‘bundle’ any Licensed Product(s) with other products or services sold for separately stated prices, offer a discount on any Licensed Product as an enticement or in exchange for purchasing other products
or services, or otherwise engage in any ‘loss leader’ or similar behavior with respect to any Licensed Product without BDSI’s prior written consent. Purdue will determine all reimbursement and launch activities related to the Product
in the Territory. Purdue will apply for formulary listings of the Product with both public and private payors, as determined by Purdue. 

(c) In the event Purdue sublicenses any of its rights in accordance with this Agreement, the activities of Sublicensees may apply to the
satisfaction of Purdue’s obligations under this Article V, provided, that, subject to the foregoing, Purdue’s obligations under this Agreement shall not be reduced or otherwise affected by any sublicensing by Purdue of its rights under
this Agreement. 
 (d) Upon the request of BDSI, but in no event more than once per Calendar Year, concurrent with Purdue’s brand
planning schedule for its own products, Purdue shall provide to BDSI in writing its proposed annual marketing, sales and distribution plan for the Licensed Products, including a high-level summary of Purdue’s, its Affiliates’, and, to the
extent available to, or in the possession of, Purdue and disclosable to BDSI without breach of any relevant agreement with the applicable Sublicensee, Sublicensees’ proposed marketing, sales and distribution strategy and tactics for the sale
and distribution of the Licensed Products in the Territory during the following Calendar Year; Purdue shall use Commercially Reasonable Efforts to obtain such information from its Sublicensees on terms permitting the disclosure thereof to BDSI
hereunder. 

  
 24 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 Section 5.02 Information Sharing. BDSI will, promptly following the
Effective Date, provide to Purdue all previous and current market research, training, marketing, sales and medical information materials for the Licensed Product in the Territory and in the U.S. available to and controlled by BDSI, except to the
extent constituting Sensitive Information. Notwithstanding anything to the contrary, the Parties shall not in any event be required under this Agreement to disclose any information or materials to other Party (i) subject to confidentiality
obligations to Third Parties or (ii) related to marketing plans, market research, pricing strategies, or similarly sensitive or strategic information related to any product other than the Licensed Product or any market other than the Territory
(the “Sensitive Information”). If BDSI is prohibited from disclosing certain information pertaining to the Licensed Product and otherwise required to be disclosed to Purdue under this Agreement due to confidentiality obligations to
any Third Parties, BDSI shall use Commercially Reasonable Efforts to seek the consent of such Third Parties to disclose any such information specifically requested by Purdue other than the Sensitive Information and, promptly following such consent,
provide such information to the extent permitted thereby. 
 ARTICLE VI 

REGULATORY COMPLIANCE 

Section 6.01 Marketing Authorization Holder. Subject to Purdue’s obligations upon expiration or termination of this
Agreement pursuant to Section 13.06, Purdue shall, upon Marketing Authorization Transfer, be the holder and owner of all Marketing Authorizations and Governmental Approvals in the Territory concerning Licensed Products and responsible for all
associated legal obligations with respect thereto. 
 Section 6.02 Maintenance of Marketing Authorizations. Subject to
its right to terminate this Agreement as provided herein, with respect to the Licensed Products, upon Marketing Authorization Transfer, Purdue agrees, at its sole cost and expense, to comply with and maintain all Marketing Authorizations and
Governmental Approvals in the Territory throughout the Term, including submitting any supplemental applications, annual reports, variations or renewals thereof that are required by Applicable Law to be obtained in order to maintain the Marketing
Authorizations and Governmental Approvals. 
 Section 6.03 Interaction with Competent Authorities. This Section 6.03
shall only be effective until such time as, and shall cease to apply once, the Pharmacovigilance Agreement is executed by the Parties. Each Party shall provide to the other Party a copy of any material correspondence or materials that it receives
from a Competent Authority in the Territory regarding any Licensed Product. Such correspondence or summary shall be provided within *** business days of receipt thereof by the relevant Party. Prior to Marketing Authorization Transfer, Purdue shall
be provided reasonable advance written notice of all material meetings, conferences, or calls with Competent Authorities in the Territory concerning any Licensed Product. Following Marketing Authorization Transfer, BDSI shall be provided reasonable

  
 25 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
advance written notice of all material meetings, conferences, or calls with Competent Authorities in the Territory concerning any Licensed Product and BDSI shall be permitted to have one
regulatory representative attend all such meetings, conferences, or calls that could reasonably be anticipated to materially concern issues that are related or relevant to BEMA generally or any BEMA-based Products other than Licensed Products. With
respect to any Licensed Product, Purdue shall provide BDSI with copies of any materials relating to any material regulatory matter in the Territory and, when reasonably practicable, shall provide copies of any documents to be presented to any
Competent Authority in respect of such matters prior to their presentation thereto, so that BDSI, if practicable, shall have an opportunity to review in advance. The materials provided to BDSI under this Article VI with respect to material
interactions with any Competent Authority will be considered Purdue’s Confidential Information. 
 Section 6.04
Post-Marketing Surveillance Costs. Purdue shall notify BDSI in writing if, at any time prior to the *** anniversary of the First Commercial Sale, it believes, in its reasonable, good faith judgment, that the total documented, direct
costs to be incurred by Purdue during *** with respect to the conduct of any post-marketing surveillance activities required by Applicable Law or the terms of any Governmental Approvals and/or Marketing Authorizations with respect to the Licensed
Product in the Territory will exceed ***. Purdue and BDSI shall, within *** of providing such notification to BDSI, engage in good faith discussions in respect of such required post-marketing surveillance activities and any potential amendments
hereto with respect thereto to which the Parties may agree. If the Parties are unable to reach written agreement on how to handle such requirement and/or any potential amendments hereto with respect thereto within *** days of the end of such ***
period, either Party shall be entitled to terminate this Agreement upon written notice to the other Party. 
 Section 6.05
Pharmacovigilance Agreement. The Parties shall use Commercially Reasonable Efforts in good faith to negotiate and execute a customary and standard forms of pharmacovigilance agreement (the “Pharmacovigilance
Agreement”) and quality agreement (with respect to the Supply Agreement) (the “Quality Agreement”) as soon as reasonably possible following the Effective Date. 

Section 6.06 Compliance. Purdue and BDSI shall comply with all Applicable Laws in exercising their rights and performing
their obligations under this Agreement, including the provision of information by Purdue and BDSI, to the extent in its possession, to each other necessary for BDSI and Purdue to comply with any mandatory reporting requirements. Each Party shall
promptly notify the other Party of any comments, responses or notices received from, or inspections by, any applicable Competent Authorities, which relate to or may impact any Licensed Product or the manufacture of any Licensed Product or the sales
and marketing of any Licensed Product, and shall promptly inform the other Party of any responses to such comments, responses, notices or inspections and the resolution of any issue raised by any Competent Authorities with respect to any Licensed
Product. 

  
 26 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 ARTICLE VII 

PATENTS AND TRADEMARKS 

Section 7.01 Maintenance of Licensed Patents and Licensed Marks. BDSI shall control and, except as explicitly set forth in
this Article VII, have full discretion in the preparation, filing, prosecution, maintenance, and defense of the Licensed Patents and Licensed Marks in the Territory, including any ex parte reexamination proceedings, inter partes review
proceeding, post grant review proceeding, derivation proceeding, action for declaratory judgment, interference proceeding or other attack upon the validity, title or enforceability of any Licensed Patents in the Territory. Upon written request by
BDSI, Purdue shall provide such assistance as may be necessary to enable BDSI to prosecute and obtain new patents related to any Licensed Improvements or Product Improvements Controlled by BDSI, with the cost and expense of such assistance, other
than with respect to Joint Improvements, to be borne by BDSI. BDSI shall keep Purdue advised by forwarding to Purdue copies of all official correspondence (including, but not limited to, applications, office actions, responses, etc.) relating to the
prosecution and maintenance of the Licensed Patents, and shall provide Purdue an opportunity to comment on any proposed responses, voluntary amendments, submissions, or other actions of any kind to be made with respect to Licensed Patents. In the
event that BDSI desires to abandon any Licensed Patents and/or Licensed Marks in the Territory, BDSI shall provide reasonable prior written notice to Purdue of its intention to abandon and a reasonable opportunity to discuss BDSI’s rationale
supporting such abandonment. In the event that BDSI decides to abandon any Licensed Patent in the Territory that contains Valid Claims that are specific to buprenorphine and Cover any Licensed Product, but does not contain any Valid Claims that
Cover any BEMA-based products incorporating any API other than buprenorphine (such a Licensed Patent, a “Buprenorphine-Specific Patent”), (a) BDSI shall provide prompt written notice of such decision to Purdue and
(b) Purdue may elect by written notice to BDSI, given within *** business days of the aforementioned notice from BDSI, continue the maintenance, defense or prosecution of such Buprenorphine-Specific Patent at Purdue’s expense, and Purdue
shall be entitled to undertake such maintenance, defense, or prosecution if BDSI does not, within *** business following such written election by Purdue, notify Purdue in writing that BDSI will instead continue the maintenance, defense or
prosecution of such Buprenorphine-Specific Patent. If BDSI does provide a subsequent notice to Purdue electing to retain control of such maintenance, defense or prosecution of a particular Licensed Patent, BDSI shall retain such control until such
time as it later again elects to abandon such Buprenorphine-Specific Patent, in which case the rights and obligations of the Parties with respect thereto hereunder shall again apply. In the event Purdue does actually assume maintenance, defense, and
prosecution of a Buprenorphine-Specific Patent pursuant to the foregoing, the ownership of such Buprenorphine-Specific Patent shall be retained by BDSI. 

Section 7.02 Filing, Prosecution, and Maintenance of Patents Covering Purdue Improvements. Purdue shall control and, except
as explicitly set forth in this Section 7.02, have full discretion in the preparation, filing, prosecution, maintenance, and defense of any Patents owned or controlled by Purdue or any Affiliate thereof Covering any Purdue Improvement,
including any ex parte reexamination proceedings, inter partes review proceeding, post grant 

  
 27 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
review proceeding, derivation proceeding, action for declaratory judgment, interference proceeding or other attack upon the validity, title or enforceability of any such Patents in the Territory.
Purdue shall keep BDSI advised with respect to the foregoing by forwarding to BDSI copies of all official correspondence (including, but not limited to, applications, office actions, responses, etc.) relating to the prosecution and maintenance of
such Patents, and shall provide BDSI a reasonable advance opportunity (to be no less than *** business days) to review and comment on any proposed patent applications, responses, voluntary amendments, submissions, or other actions of any kind to be
made with respect to any such Patents, and Purdue shall reasonably take into consideration any reasonable comments made by BDSI with respect thereto. In the event that Purdue desires to abandon any such Patents Covering any Purdue Improvement,
Purdue shall provide reasonable prior written notice to BDSI of Purdue’s intention to abandon and a reasonable opportunity to discuss Purdue’s rationale supporting such abandonment. 

Section 7.03 Prosecution of Infringement. During the Term, each Party shall give prompt written notice to the other Party
of any Third Party act in the Territory that (a) concerns any product(s) that contain buprenorphine as the sole API and (b) may infringe the Licensed Patents and/or the Licensed Marks in the Territory. BDSI shall, as between the Parties,
have the sole and exclusive right with respect to Licensed Marks and Licensed Patents, but not, in either case, the obligation, to bring and control any action or proceeding (i) concerning any potential or actual infringement of the Licensed
Patents or Licensed Marks or (ii) concerning any potential or actual misappropriation of any Licensed Know-How. If BDSI is unable to initiate or to prosecute such action solely in its own name or it is otherwise Commercially Reasonable and
reasonably advisable to obtain an effective or interim remedy, Purdue shall, if and as requested by BDSI and at BDSI’s sole expense (which shall be reasonable and documented), join such action and take such other reasonable steps requested by
BDSI as are necessary for BDSI to initiate litigation to prosecute and maintain such action, provided, that, under no circumstances will Purdue be obligated to, amend or alter any of the terms of this Agreement in a manner adverse to Purdue’s
interests in order to enable BDSI to initiate litigation to prosecute and maintain such action. Purdue shall provide, at BDSI’s sole expense (which shall be reasonable and documented), such other assistance and cooperation to BDSI as may be
necessary to prosecute any action against such Third Party. Any damages, monetary awards, or other amounts recovered or received in settlement by BDSI shall be applied proportionately first to defray the unreimbursed reasonable, documented costs and
expenses (including reasonable attorneys’ fees) incurred by Purdue and BDSI in the action, with the remaining balance thereof (A) to be retained by BDSI if and to the extent that the amounts recovered or received by BDSI pertain to
Licensed Patents other than any Buprenorphine-Specific Patents or that pertain to Buprenorphine-Specific Patents but are recovered or received with respect to the manufacture, use, sale, or import of a product other than a Licensed Product or
(B) to be split *** to Purdue and *** to BDSI if and to the extent that the amounts recovered or received by BDSI directly pertain to any Buprenorphine-Specific Patents and the manufacture, use, sale, or import of a Licensed Product. 

Section 7.04 Infringement Claimed by Third Parties. In the event a Third Party commences a judicial or administrative
proceeding against a Party and such proceeding, other than a proceeding to which Section 7.01 applies, pertains to the manufacture, use, sale, 

  
 28 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
marketing, or import of a Licensed Product in the Territory by or on behalf of Purdue, an Affiliate thereof, or a Sublicensee (the “Third Party Claim”), or threatens to commence
such a Third Party Claim, the Party against whom such proceeding is threatened or commenced shall give prompt notice to the other Party and the Parties shall reasonably consult with each other with respect to possible strategies for addressing the
alleged infringement. 
 Section 7.05 Payment of Costs and Expenses. Upon its receipt of a reasonably detailed invoice
setting forth a Party’s reasonable, documented costs and expenses incurred pursuant to any provision of this Article VII relating to the Territory, for which the other Party shall be liable in accordance with this Article VII, such other Party
shall pay such costs and expenses within *** of receipt of an invoice therefor. 
 ARTICLE VIII 

CONFIDENTIALITY 

Section 8.01 Confidentiality. The Parties agree that, for the Term and for *** thereafter, each Party will keep completely
confidential and will not publish, submit for publication or otherwise disclose, and will not use for any purpose except for the purposes contemplated by this Agreement or the Supply Agreement (including but not limited to the exercise or
enforcement of rights or performance of obligations under this Agreement or the Supply Agreement), any Confidential Information of the other Party. 

Section 8.02 Authorized Disclosure. Each Party may disclose Confidential Information of the other Party to the extent that
such disclosure is: 
 (a) made in response to a valid order of a court of competent jurisdiction; provided, however, that in each case such
disclosing Party will, to the extent reasonably practicable, (i) first have given written notice to the other Party and given such other Party a reasonable opportunity to take appropriate action and (ii) cooperate with such other Party as
necessary to obtain an appropriate protective order or other protective remedy or treatment; provided, further, that in each case, the Confidential Information disclosed in response to such court or governmental order will be limited to that
information which is legally required to be disclosed in response to such court or governmental order, as determined in good faith by the Party that is obligated to disclose Confidential Information pursuant to such order; 

(b) otherwise required to be disclosed by any applicable law, rule, or regulation (including, without limitation, the U.S. federal securities
laws and the rules and regulations promulgated thereunder) or the requirements of any stock exchange to which a Party or any Affiliate thereof is subject; provided, however, that the Party that is so required will provide such other Party with
written notice of such disclosure reasonably in advance thereof to the extent reasonably practicable and reasonable measures will be taken to assure confidential treatment of such information, including such measures as may be reasonably requested
by the disclosing Party with respect to such Confidential Information; 

  
 29 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 (c) made by such Party, in connection with the performance of this Agreement or the Supply
Agreement, to such Party’s Affiliates, licensees, sublicensees, contractors, directors, officers, employees, consultants, representatives or agents, or to other Third Parties, in each case on a need to know basis and solely to use such
information for business purposes relevant to and permitted or required by this Agreement or the Supply Agreement, and provided that (i) each such party to whom such Confidential Information is disclosed is bound in writing to non-use and
non-disclosure obligations substantially as protective as those set forth in this Agreement and (ii) the Party making such disclosure shall be liable for such Third Parties’ compliance with such obligations; or 

(d) made by such Party to: 

(i) actual or potential acquirers, licensees, licensors, investment bankers, investors, merger targets, lenders, or financial
institutions, specifically excluding, however, (a) non-governmental health care providers and (b) health care payors, except, in the case of (a) and (b), as required by applicable law, rule, or regulation or order or request of any
Governmental Authorities; or 
 (ii) any Third Party to the extent such Party or an Affiliate thereof is contractually
required, as of the Effective Date, to disclose any Confidential Information of the other Party to such Third Party in order to satisfy its obligations under an agreement with such Third Party as it relates to the satisfaction of such Party’s
obligations hereunder or under the Supply Agreement; 
 and provided in each case under this clause (d) that (I) each individual
and entity to whom such Confidential Information is disclosed is bound in writing to non-use and non-disclosure obligations substantially as protective as those set forth in this Agreement and (II) the Party making such disclosure shall be liable
for such Third Parties’ compliance with such obligations. 
 Any Party making a disclosure permitted under clause (d)(i) of this
Section 8.02 shall promptly notify the other Party of such disclosure, including the name of the person or entity to which the disclosure was made, unless such notice is prohibited or limited by applicable law, rule, or regulation or the terms
of any contractual obligation of confidentiality between such Party and any Third Party, in which case the Party making such disclosure shall instead use Commercially Reasonable Efforts to minimize the amount of the other Party’s Confidential
Information to be disclosed, or delay the disclosure of the other Party’s Confidential Information, to the extent reasonably possible without, as determined in good faith by the Party making such disclosure, adversely affecting the
negotiations, transaction (or terms thereof), or existing relationship in connection with which such disclosure is being made. 

Section 8.03 Disclosure of Agreement. Neither Party shall release to any Third Party or publish in any way
any non-public information with respect to the terms of this Agreement or the terms of the Supply Agreement without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided, in each case with respect
to such releases or disclosures requiring such consent pursuant to this Section 8.03, that (i) each individual and  

  
 30 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
entity to whom such information is disclosed is bound in writing to non-use and non-disclosure obligations substantially as protective as those set forth in this Agreement and (ii) the Party
making such disclosure shall be liable for such Third Parties’ compliance with such obligations. Notwithstanding the foregoing, a Party may disclose the terms of this Agreement or the Supply Agreement to: 

(x) actual or potential acquirers, licensees, licensors, investment bankers, investors, merger targets, lenders, or financial
institutions, specifically excluding, however, (a) non-governmental health care providers and (b) health care payors, except, in the case of (a) and (b), as required by applicable law, rule, or regulation or order or request of any
Governmental Authorities; or 
 (y) any Third Party to the extent a Party or an Affiliate thereof is contractually required,
as of the Effective Date, to disclose any non-public portion of this Agreement, the Supply Agreement, or any terms hereof or thereof to such Third Party in order to satisfy its obligations under an agreement with such Third Party as it relates to
the satisfaction of such Party’s obligations hereunder or under the Supply Agreement; 
 and provided in each case under this sentence
that (I) each individual and entity to whom such Confidential Information is disclosed is bound in writing to non-use and non-disclosure obligations substantially as protective as those set forth in this Agreement, (II) the Party making such
disclosure shall be liable for such Third Parties’ compliance with such obligations, and (III) any Party making a disclosure permitted under clause (x) of this sentence shall promptly notify the other Party of such disclosure, including
the name of the person or entity to which the disclosure was made, unless such notice is prohibited or limited by applicable law, rule, or regulation or the terms of any contractual obligation of confidentiality between such Party and any Third
Party, in which case the Party making such disclosure shall instead use Commercially Reasonable Efforts to minimize the nonpublic portion of this Agreement, the Supply Agreement, or terms hereof or thereof to be disclosed, or delay the disclosure of
the nonpublic portion of this Agreement, the Supply Agreement, or terms hereof or thereof, to the extent reasonably possible without, as determined in good faith by the Party making such disclosure, adversely affecting the negotiations, transaction
(or terms thereof), or existing relationship in connection with which such disclosure is being made. 
 Nothing in this Section 8.03 shall prohibit
either Party from filing this Agreement or the Supply Agreement as required by any applicable, laws, rules, or regulations, including those of the Securities and Exchange Commission, national securities exchanges (including those located in
countries outside of the United States) or the Nasdaq Stock Market; provided the disclosing Party (1) discloses only such information required to be disclosed in order to comply with such requirements, as reasonably determined by such Party,
including, to the extent reasonably available or applicable requesting confidential treatment of this Agreement or the Supply Agreement (after providing a reasonable opportunity for consultation by the other Party) and filing this Agreement or the
Supply Agreement in redacted form and (2) to the extent reasonably practicable, reasonably in advance of such disclosure informs the other Party of the contents of the proposed disclosure. The Parties agree to cooperate with respect to requests
for confidential treatment to be submitted to the Securities and Exchange Commission or any similar foreign authority with respect to certain portions of this Agreement or Supply Agreement and any redactions thereof for such purposes. 

  
 31 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 ARTICLE IX 

REPRESENTATIONS AND WARRANTIES 

Section 9.01 Corporate Power. As of the Effective Date, each Party hereby represents and warrants that such Party is duly
organized and validly existing under the laws of the jurisdiction of its organization and has full power and authority to enter into this Agreement and the transactions contemplated hereby and to carry out the provisions hereof. 

Section 9.02 Due Authorization. As of the Effective Date, each Party hereby represents and warrants that such Party is duly
authorized to execute and deliver this Agreement and to perform its obligations hereunder. 
 Section 9.03 Binding
Obligation. As of the Effective Date, each Party hereby represents and warrants that this Agreement is a legal and valid obligation binding upon it and is enforceable in accordance with its terms, except that the enforcement of the rights
and remedies created hereby is subject to bankruptcy, insolvency, reorganization and similar laws of general application affecting the rights and remedies of creditors and that the availability of the remedy of specific performance or of injunctive
relief is subject to the discretion of the court before which any proceeding therefor may be brought. As of the Effective Date, each Party represents and warrants that the execution, delivery and performance of this Agreement by such Party does not
conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having authority over
it. 
 Section 9.04 Legal Proceedings. As of the Effective Date, each Party hereby represents and warrants to the other
Party that there is no action, suit or proceeding pending against or affecting, or, to the Knowledge of such Party, threatened against or affecting that Party, or any of its assets, before any Governmental Authority in the Territory that would, if
decided against such Party, have a material adverse impact on the Commercialization of the Licensed Product in the Territory or that Party’s ability to consummate the transactions and perform the obligations contemplated by this Agreement. 

Section 9.05 No Guarantee of Success. Purdue and BDSI acknowledge and agree that nothing in this Agreement will be
construed as representing any estimate or projection of (i) the successful Commercialization of any Licensed Product under this Agreement, (ii) the number of Licensed Products that will or may be successfully Commercialized under this
Agreement, or (iii) anticipated sales or the actual value of any Licensed Products that may be successfully Commercialized under this Agreement. Neither Party makes any warranties, express or implied, or covenants concerning the success of the
Commercialization of any Licensed Products. 
 Section 9.06 Sufficient Rights. BDSI represents and warrants that
(a) it has and shall maintain during the Term of this Agreement (i) an exclusive license to or ownership of, as 

  
 32 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
applicable, the Licensed Technology, the Licensed Marks and any other intellectual property rights which are the subject of Purdue’s licenses under this Agreement and (ii) the right to
grant the licenses described in this Agreement and fulfill its obligations herein, and (b) the grant of such licenses by BDSI will not conflict with or violate any of the terms of any agreement of BDSI concerning the Licensed Technology or the
Licensed Marks. 
 Section 9.07 No Infringement. BDSI represents and warrants that, to BDSI’s Knowledge as of the
Effective Date, no valid claim of any issued patent owned by a Third Party will be infringed by the Commercialization of the Current Product in the Territory. 

Section 9.08 Intellectual Property. BDSI represents and warrants that there are no other intellectual property
rights owned or Controlled by BDSI or any of its Affiliates as of the Effective Date, other than the rights in the Licensed Technology, which cover the Current Product or would otherwise prevent Purdue from Commercializing the Current Product in the
Territory as set forth herein. 
 Section 9.09 Disqualification. Each Party represents and warrants to the
other that it has never been and is not currently under prosecution by Health Canada for behavior that would contravene Applicable Law, and each Party agrees that it will not obtain advice or assistance from any individual prosecuted by Health
Canada or another health Regulatory Authority, under Applicable Law, or disciplined for contravention of their professional code of ethics. Each Party represents and warrants to the other that it has no Knowledge of any circumstances that may
affect the accuracy of the foregoing warranties and representations, including, but not limited to, investigations of, or proceedings against, it or any person or entity with which it is associated or that provides services to such Party, and such
Party will immediately notify the other in writing if it becomes aware of any such circumstances during the term of this Agreement. 

Section 9.10 Arius. Parent represents and warrants that, as of the Effective Date, (i) it is the sole shareholder of
Arius Two, Inc. (“Arius Two”) and Arius, (ii) Arius Two owns title to those Licensed Patents relating to the Licensed Products for which Arius Two is identified as the assignee thereof on Exhibit C, and (ii) Arius
is the exclusive licensee of Arius Two with respect to such Licensed Patents.  
 Section 9.11 Compliance with
Laws. Each Party represents and warrants to the other that it or its Affiliates have all permits, licenses and authorizations required by any Governmental Authority to be obtained by such Party in connection with this Agreement, or the grant
of any intellectual property rights granted hereunder, except for the matters contemplated by Section 2.01, to which this Section 9.11 does not apply. 

Section 9.12 Disclaimer. EXCEPT FOR THE EXPRESS REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS AGREEMENT
(INCLUDING THOSE SET FORTH ABOVE IN THIS ARTICLE IX) AND THE SUPPLY AGREEMENT, AND WITHOUT LIMITATION OF THE CONTRACTUAL RIGHTS AND OBLIGATIONS OF THE PARTIES IN THE QUALITY AGREEMENT, THE PARTIES MAKE NO REPRESENTATIONS AND GRANT NO WARRANTIES,
EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND THE PARTIES EACH 

  
 33 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
SPECIFICALLY DISCLAIM ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR USE OR PURPOSE. 

ARTICLE X 

INDEMNIFICATION; INSURANCE; LIMITATION OF LIABILITY 

Section 10.01 Indemnification by BDSI. Subject to Section 10.03, BDSI hereby agrees to defend, indemnify and
hold harmless Purdue, its Affiliates, and its and their respective officers, directors, employees, agents, other representatives, and successors and assigns (“Purdue Indemnitees”) from and against all suits, claims, proceedings or
causes of action brought by Third Parties (“Claims”) brought against any Purdue Indemnitee, and all associated damages, liabilities, expenses and/or losses, including reasonable legal expenses and reasonable attorneys’ fees
(collectively, “Losses”), arising out of BDSI’s, its Affiliates’, and its and their respective officers’, directors’, employees’, contractors’, agents’, other representatives’, and
successors’ and assigns’ (i) negligence or willful misconduct with respect to the subject matter of this Agreement, (ii) failure to comply with any Applicable Law with respect to the subject matter of this Agreement,
(iii) breach of this Agreement, or (iv) manufacture, use, sale, offer for sale, development, commercialization, import, or export of any Licensed Product(s) within or outside the Territory; provided, that BDSI shall not have any such
obligation if and to the extent any such Claims or Losses result from any Purdue Indemnitees’ (A) negligence or willful misconduct, (B) failure to comply with Applicable Laws with respect to the subject matter of this Agreement, or
(C) breach of this Agreement or the Supply Agreement. 
 Section 10.02 Indemnification by Purdue. Subject to
Section 10.03, Purdue hereby agrees to indemnify, defend and hold harmless BDSI, its Affiliates, and its and their respective officers, directors, employees, agents, other representatives, and successors and assigns (collectively, “BDSI
Indemnitees”) from and against all Claims brought against any BDSI Indemnitee, and any associated Losses, arising out of Purdue’s, its Affiliates’, and Sublicensees’, and its and their respective officers’,
directors’, employees’, contractors’, agents’, other representatives’, and successors’ and assigns’ (i) negligence or willful misconduct with respect to the subject matter of this Agreement, (ii) failure
to comply with any Applicable Law with respect to the subject matter of this Agreement, (iii) breach of this Agreement, or (iv) manufacture of Licensed Product not supplied to Purdue pursuant to the Supply Agreement or use, development,
Commercialization, import or export of any Licensed Product(s), provided, that Purdue shall not have any such obligation if and to the extent any such Claims or Losses result from any BDSI Indemnitees’ (A) negligence or willful misconduct,
(B) failure to comply with Applicable Laws with respect to the subject matter of this Agreement , or (C) breach of this Agreement or the Supply Agreement. 

Section 10.03 Indemnification Procedures. Each Party’s agreement to indemnify, defend, and hold harmless under
Section 10.01 or 10.02, as applicable, is conditioned upon the indemnified Party (a) providing written notice to the indemnifying Party of any Claim or Loss 

  
 34 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
arising out of the indemnified matter as soon as reasonably practicable, and in any event no later than within *** after the indemnified Party has actual Knowledge of such Claim or Loss,
provided, however, that, if the Party entitled to indemnification fails to promptly notify the indemnifying Party pursuant to this subsection (a), the indemnifying Party will only be relieved of its indemnification obligation under this Article X to
the extent materially and adversely prejudiced by such failure or delay, (b) permitting the indemnifying Party to assume control over the investigation of, preparation and defense against, and settlement or voluntary disposition of any Claim,
(c) assisting the indemnifying Party, at the indemnifying Party’s reasonable expense, in the investigation, preparation, defense, and settlement or voluntary disposition of any such Claim or Loss, and (d) not compromising, settling,
or entering into any voluntary disposition of any such Claim without the indemnifying Party’s prior written consent, which consent shall not be unreasonably withheld. In no event may the indemnifying Party compromise, settle, or enter into any
voluntary disposition of any Claim in any manner that explicitly admits material fault or wrongdoing on the part of the indemnified party, incurs non-indemnified liability (including any payment obligation) on the part of the indemnified party,
would reasonably be anticipated to result in criminal liability on the part of the indemnified party, or would reasonably be anticipated to have a material and adverse effect on the business of the indemnified party without the prior written consent
of the indemnified party, and in no event may the indemnifying Party settle, compromise, or agree to any voluntary disposition of any matter subject to indemnification hereunder in any manner which would, in the case of any settlement, compromise or
voluntary disposition effected by Purdue pursuant to its rights or obligations under Section 10.02, reasonably be anticipated to have a material likelihood of adversely affecting any portion of the Licensed Technology or the Licensed Marks, or
BDSI’s, its Affiliates’, or any of their respective Third Party licensees’ or Third Party sublicensees’ ability to manufacture, develop, or commercialize Licensed Products or any other BEMA-based Products anywhere in the world,
without BDSI’s prior written consent. 

  
 35 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 Section 10.04 Insurance. 

(a) Except as otherwise provided below, BDSI shall maintain insurance, including commercial general liability, product liability and, for
clinical trials it sponsors, clinical trials liability insurance (with such clinical trials coverage in such amounts as will be commercially reasonable to cover the conduct of the relevant studies including, without limitation, coverage as may be
required by local law or regulation in countries outside of the United States), and workers compensation and employer’s liability insurance with respect to its activities under this Agreement regarding Licensed Products in such amount as it
customarily maintains with respect to similar activities for its other products, but not less than (i) US$*** each occurrence and US$*** aggregate for commercial general liability, (ii) US$*** each occurrence and US$*** aggregate for
product liability, and (iii) such amount as is reasonable and customary in the Canadian pharmaceutical industry for workers compensation and employer’s liability. Such coverage shall be maintained for *** following expiration or
termination of this Agreement or if such coverage is of the “claims made” type, for *** following expiration or termination of this Agreement. Upon written request, BDSI shall provide Purdue with written evidence of the required coverage.
Coverage may be in the form of primary insurance or a combination of primary and excess insurance. 
 (b) Except as otherwise provided
below, Purdue shall maintain insurance, including commercial general liability, product liability, workers compensation and employer’s liability insurance, with respect to its activities under this Agreement regarding Licensed Products in such
amount as it customarily maintains with respect to similar activities for its other products, but not less than (i) US$*** each occurrence and US$*** aggregate for commercial general liability, (ii) US$*** each occurrence and US$***
aggregate for product liability and (iii) such amount as is reasonable and customary in the Canadian pharmaceutical industry for workers compensation and employer’s liability. Such coverage shall be maintained for *** following expiration
or termination of this Agreement or, if such coverage is of the “claims made” type, for *** following expiration or termination of this Agreement. Upon written request, Purdue shall provide BDSI with written evidence of the required
coverage. Coverage may be in the form of primary insurance or a combination of primary and excess insurance. In the event that Purdue, any Affiliate thereof, or any Sublicensee sponsors or conducts a clinical trial involving a Licensed Product in
the Territory, it shall make Commercially Reasonable additions to the insurance coverage described in this Section 10.04(b) with respect to such trial, including clinical trial insurance coverage. Notwithstanding the foregoing, it is hereby
acknowledged by BDSI that, as of the Effective Date, no such clinical trials are currently planned or contemplated by Purdue. 
 (c) Each
Party shall provide the other Party *** notice of any material change, cancellation or non-renewal of any required insurance under this Agreement. In the event of a material change, cancellation, or non-renewal in coverage, each Party shall replace
such coverage to comply with this Agreement so that there is no lapse of coverage for any time period. It is understood that the above-required insurance shall not be construed to create a limit of either Party’s liability, with respect to its
indemnification obligations or otherwise, under this Agreement. 

  
 36 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 Section 10.05 Limitation of Liability. IN NO EVENT WILL EITHER PARTY BE
LIABLE TO THE OTHER PARTY OR TO ANY AFFILIATE THEREOF OR TO ANY THIRD PARTY CLAIMING UNDER OR THROUGH SUCH PARTY OR ANY OF ITS AFFILIATES FOR LOST PROFITS, LOST REVENUE, LOST SAVINGS, LOSS OF USE, DAMAGE TO GOODWILL, OR FOR ANY SPECIAL, INDIRECT,
INCIDENTAL, EXEMPLARY CONSEQUENTIAL OR PUNITIVE DAMAGES, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY (WHETHER BREACH OF CONTRACT, NEGLIGENCE, STRICT LIABILITY, OR OTHERWISE) AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES, ARISING UNDER ANY CAUSE OF ACTION AND ARISING IN ANY WAY OUT OF THIS AGREEMENT, PROVIDED THAT, NOTWITHSTANDING THE FOREGOING, THE FOREGOING LIMITATION WILL NOT LIMIT EITHER PARTY’S (A) INDEMNIFICATION OBLIGATIONS FOR CLAIMS OR
LOSSES UNDER ARTICLE 10.01 OR 10.02 OR (B) LIABILITY FOR PATENT INFRINGEMENT OR ANY BREACH OF ARTICLE VIII OR SECTION 11.10 OR 11.14. 

ARTICLE XI 
 COVENANTS

 Section 11.01 Books and Records. Except as otherwise explicitly provided herein, Purdue shall maintain complete
and accurate written records of all of its and its Affiliates’ activities with respect to the Licensed Products, or other exercise of rights or performance of obligations hereunder, for a minimum of *** following the end of the Calendar Year to
which they pertain, which records may be subject to audit and inspection by BDSI pursuant to Section 14.11. BDSI shall maintain complete and accurate written of all of its and its Affiliates’ activities with respect to the Licensed
Products, or other exercise of rights or performance of obligations hereunder for a minimum of *** following the end of the Calendar Year to which they pertain, which records may be subject to audit and inspection by Purdue pursuant to
Section 14.11. Each Party covenants and agrees that it shall permit representatives of the other Party (or any Third Party allowed to be granted such rights by the other Party under this Agreement) to exercise such inspection rights with
regards to such Party’s Books and Records solely as expressly set forth in Section 14.11. 
 Section 11.02 Marketing
Expenses. Purdue covenants and agrees that, as between Purdue and BDSI, Purdue shall be solely responsible for the cost and implementation of all of its own marketing, sales, promotional and related activities concerning the
Commercialization of the Licensed Products in the Territory. 
 Section 11.03 Affiliates. Without limitation of
Section 3.02(c), each of Purdue and BDSI shall cause its respective Affiliates who engage in the performance of any activities, exercise any rights, assume any obligations hereunder, or have access to, or know or use, the other Party’s
Confidential Information, to comply with all obligations applicable to such Affiliates in connection therewith under this Agreement. Each Party shall be responsible and liable for any performance of its obligations hereunder by any of its Affiliates
and their compliance with the terms of this Agreement in connection therewith, and any breach of the 

  
 37 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
terms of this Agreement by any Affiliate of a Party shall be deemed a breach of this Agreement by such Party. Notwithstanding anything to the contrary, however, no Affiliate of Purdue shall be
entitled to engage in any Commercialization of Licensed Product in the Territory without BDSI’s prior written consent, which consent shall not be unreasonably withheld. 

Section 11.04 Compliance. 

(a) Purdue covenants and agrees that it shall comply in all material respects with all Applicable Laws in connection with its
(i) Commercialization of, or other activities with respect to, the Licensed Products and Demonstration Samples in the Territory, and (ii) other exercise of rights or performance of obligations hereunder, and Purdue shall cause all of its
Affiliates, and shall use Commercially Reasonable Efforts to cause its Sublicensees and subcontractors, to comply with the foregoing obligation. Notwithstanding anything to the contrary, any failure of Purdue, any Affiliate thereof, or any
Sublicensee to adhere to any Applicable Laws in the Territory concerning the handling of narcotics which materially adversely affects BDSI’s, its Affiliates’, or any of its or their licensees’ or sublicensees’ future manufacture,
use, shipment, handling, sale, marketing, or distribution of buprenorphine (or any product incorporating buprenorphine) in connection with the Licensed Technology shall be deemed a material breach of this Agreement entitling BDSI, subject to prior
notice and, with respect solely to the first such failure, a right to cure in the same manner as provided in Section 13.02(b), to terminate this Agreement immediately pursuant to Section 13.02(b). For the avoidance of doubt, the foregoing
covenant does and shall not apply to, and BDSI acknowledges and agrees that Purdue is not assuming any responsibility or liability under any circumstances for, the use, possession, distribution, advertising or promotion of any Licensed Products or
Demonstration Samples or any failure to comply with Applicable Laws concerning the handling of any narcotics, including buprenorphine, by or on behalf of BDSI, any of its Affiliates or any Third Party on its or their behalf or for its or their
benefit prior to the Marketing Authorization Transfer. 
 (b) BDSI covenants and agrees that it shall comply in all material
respects with all Applicable Laws in connection with its (i) activities with respect to the Licensed Products and Demonstration Samples in the Territory and (ii) other exercise of rights or performance of obligations hereunder, and BDSI
shall cause all of its Affiliates and use Commercially Reasonable Efforts to cause its subcontractors to comply with the foregoing obligation. 

Section 11.05 Reports. Purdue covenants and agrees that, except as otherwise specified in this Agreement, Purdue shall,
following Marketing Authorization Transfer, have the obligation and responsibility for and shall make any and all necessary reports to each Competent Authority with respect to the Licensed Product in the Territory and shall provide BDSI with a
complete copy of any such report as soon as reasonably possible but in any event within *** of the date of its submission of the report to each Competent Authority. Purdue covenants and agrees that, except as otherwise specified in this Agreement,
Purdue shall, following Marketing Authorization Transfer, have the obligation and responsibility for and shall make any and all necessary reports in respect of the safe and lawful handling of the Licensed Products as a narcotic substance to each
Competent Authority, and shall provide BDSI with a complete copy of any such report as soon as reasonably possible but in any event within *** of the date of submission of the report to each Competent Authority. 

  
 38 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 Section 11.06 Further Actions. Upon the terms and subject to the
conditions hereof, each of the Parties shall use its Commercially Reasonable Efforts to (a) take, or cause to be taken, all appropriate action and do, or cause to be done, all things necessary, proper or advisable under Applicable Law or
otherwise to consummate and make effective the transactions contemplated by this Agreement, (b) obtain from Competent Authorities any consents, licenses, permits, waivers, approvals, authorizations or orders required to be obtained or made by
the Parties in connection with the authorization, execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement, and (c) make all necessary filings, and thereafter make any other required
submissions, with respect to this transaction under (i) the United States’ Securities Exchange Act of 1934, as amended and the United States’ Securities Act of 1933, as amended, and the rules and regulations thereunder and any other
applicable securities laws and (ii) any other Applicable Law. The Parties shall cooperate with each other in connection with the making of all such filings, including by providing copies of all such documents to the other Party’s counsel
(subject to appropriate confidentiality restrictions) prior to filing and, if requested, by accepting all reasonable additions, deletions or changes suggested in connection therewith. 

Section 11.07 Equitable Relief. The Parties understand and agree that because of the difficulty of measuring economic
losses to the non-breaching Party as a result of a breach of the covenants set forth in Article VIII or in this Article XI, and because of the immediate and irreparable damage that may be caused to the non-breaching Party for which monetary damages
may not be a sufficient remedy, the Parties agree that the non-breaching Party may be entitled to seek specific performance, temporary and permanent injunctive relief, and such other equitable remedies to which it may then be entitled against the
breaching Party. This Section 11.07 shall not limit any other legal or equitable remedies that the non-breaching Party may have against the breaching Party for violation of the covenants set forth in Article VIII or in this Article XI. The
Parties agree that the non-breaching Party shall have the right to seek relief for any violation or threatened violation of Article VIII or this Article XI by the breaching Party from any court of competent jurisdiction in any jurisdiction
authorized to grant the relief necessary to prohibit the violation or threatened violation of Article VIII or this Article XI. This Section 11.07 shall apply with equal force to the breaching Party’s Affiliates. 

Section 11.08 Competing Products. During the Term, ***, neither BDSI (or any Affiliate thereof) nor Purdue (or Affiliate
thereof) shall, directly or indirectly (including by way of acquisition or in license from a Third Party, but excluding by way of out license to a Third Party by an Affiliate of Purdue), register or apply for Governmental Approval, sell, offer for
sale, commercially distribute, or otherwise commercialize (defined in manner similar to that of Commercialize, but with respect to products other than Licensed Products) any BDSI Competing Product in the Territory, and each Party shall ensure that
its Affiliates comply with the foregoing obligations, subject to the remaining portions of this Section 11.08. Each Party shall ensure that its Affiliates comply with the foregoing obligations. Notwithstanding the preceding sentence,

  
 39 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
*** rights to (a) develop, manufacture, have manufactured, or use, in the Territory any products *** which are intended solely for commercial sale to Third Parties located outside the
Territory, (b) develop, manufacture, have manufactured, use, sell, or offer for sale in the Territory any products *** or (c) otherwise exercise BDSI’s reserved rights under Section 3.02(a) or rights granted under
Section 3.06 shall not be limited in any manner by this Agreement. Notwithstanding anything to the contrary in this Section 11.08, ***. 

Section 11.09 Right of First Negotiation. 

(a) If BDSI determines that it will (i) seek to grant any license to a Third Party that includes the right to market or promote an ROFN
Product in the Territory or (ii) develop (for purposes of obtaining Marketing Authorization thereof in the Territory), sell, market, distribute, or otherwise commercialize any ROFN Product in the Territory (itself or via any Affiliate or Third
Party) pursuant to Marketing Authorization thereof in the Territory, then BDSI shall promptly notify Purdue thereof in writing (the “ROFN Notice”). Purdue shall have [thirty (30)] days from the date it receives such ROFN Notice (the
“ROFN Notice Period”) to notify BDSI in writing of Purdue’s desire to negotiate an agreement under which Purdue (or an Affiliate thereof) would be granted rights to develop and/or commercialize such ROFN Product in the
Territory (a “Negotiation Notice”). ***. If Purdue does not provide BDSI with a Negotiation Notice within the ROFN Notice Period, or affirmatively notifies BDSI during such ROFN Notice Period that it will not pursue an agreement
with BDSI with respect to such ROFN Product in the Territory, then Section 11.08 will not apply to, and shall terminate with respect to, such ROFN Product in the Territory. 

(b) If Purdue delivers a timely Negotiation Notice, the Parties shall enter into a *** negotiation period *** (the “Negotiation
Period”), during which time the Parties shall negotiate *** with each other in good faith concerning a license to Purdue with respect to the development and/or commercialization of the applicable ROFN Product in the Territory. Not less than
*** prior to the end of the Negotiation Period, BDSI shall forward its last term sheet proposal to Purdue ***. 
 (c) In the event Purdue
provides a Negotiation Notice as provided above, BDSI will promptly provide Purdue all material information and data in the possession and Control of BDSI that is directly related to the applicable ROFN Product, or its development and/or
commercialization, in the Territory, that would be reasonably pertinent to either an understanding of, or the subject of, the license, as reasonably requested by Purdue as part of Purdue’s due diligence with respect to such license. 

(d) If BDSI and Purdue do not mutually execute a definitive agreement with respect to a license during the Negotiation Period *** or Purdue
declines in writing to enter into a license for the applicable ROFN Product, then Section 11.08 will not apply to, and shall terminate with respect to, such ROFN Product in the Territory. 

Section 11.10 Right of First Refusal. Prior to BDSI entering into any license granting rights to any Third Party under any
Patents owned or otherwise controlled by BDSI Covering an ROFR Product (“ROFR Patents”) to market and sell such ROFR Product in the Territory (a 

  
 40 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
“Third Party License”), BDSI must notify Purdue in writing of the material terms of such Third Party License that were acceptable to BDSI and such Third Party (the “Third
Party Offer”). Purdue will have *** from the date of such notice to elect in its sole discretion to enter into an agreement with BDSI granting Purdue rights under such ROFR Patents to market and sell such ROFR Product in the Territory on
the terms of the Third Party Offer and otherwise on commercially reasonable terms and conditions (“ROFR Product License Agreement”). 

If Purdue so elects to enter into an ROFR Product License Agreement with BDSI, BDSI will immediately cease all material discussions with any
Third Party regarding any license to market and sell the applicable ROFR Product(s) under the ROFR Patents in the Territory and the Parties shall use Commercially Reasonable Efforts in good faith to negotiate and execute an ROFR Product License
Agreement with each other. If (i) Purdue does not, within such *** period, elect in writing to enter into an ROFR Product License Agreement for such ROFR Product(s) or (ii) Purdue does make such an election but, despite BDSI’s
Commercially Reasonable Efforts in good faith to negotiate and execute a ROFR Product License Agreement with Purdue, the Parties do not execute such an agreement within *** such election by Purdue, BDSI may pursue or resume discussions with any
Third Party regarding the applicable Third Party License and enter into an agreement including such Third Party License with such Third Party. Upon execution of such an agreement with a Third Party, Purdue, or any Affiliate thereof with respect to
any particular Third Party Offer’s terms for any particular ROFR Product(s) pursuant to this Section 11.10, the Parties’ rights and obligations under this Section 11.10 shall terminate and Section 11.08 will not apply to,
and shall terminate with respect to, all ROFR Products in the Territory, provided that the material terms of such Third Party License shall not be materially more favorable to such Third Party than those last proposed to Purdue by BDSI. In the
event such material terms of such Third Party License are to be more favorable to such Third Party than those last proposed to Purdue by BDSI, then BDSI shall restart the process described in this Section 11.10. 

*** 
 Section 11.11
No Encumbrances. Except to the extent Purdue may assign this Agreement under Section 14.01, Purdue shall not, without the prior written consent of BDSI, such consent not to be unreasonably withheld, sell, license or sublicense
(except as permitted by Section 3.02(a)), encumber or otherwise transfer to a Third Party any of Purdue’s rights in Governmental Approvals, Marketing Authorizations, or Regulatory Filings in respect to any Licensed Product. 

Section 11.12 Cross-Border Protections. It is understood that Purdue receives no rights with respect to any Licensed
Product or Licensed Technology or otherwise by virtue of this Agreement in any countries or territories other than the Territory. For greater certainty, but without limiting the generality of anything otherwise contained in this Agreement, it is
expressly understood and agreed that Purdue shall: 
 *** 

  
 41 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 Purdue shall maintain complete and accurate written records in respect of its shipments of
Licensed Products to its and their Affiliates, Sublicensees, distributors, and customers, and shall cause its Affiliates, Sublicensees, and distributors to maintain complete and accurate written records in respect of shipments of Licensed Products
to customers, for a minimum of *** following the end of the Calendar Year to which they pertain, which records other than distributors’ records may be subject to audit and inspection by BDSI pursuant to Section 14.11 once per Calendar
Year, provided that Purdue shall, upon BDSI’s request, promptly audit such records of any of its distributors pursuant to the terms of the applicable agreement(s) therewith and share the results of such audit with BDSI. 

ARTICLE XII 
 PRODUCT
RECALL 
 Section 12.01 Product Recall Determination. If at any time or from time to time, a Competent Authority
requests or requires Purdue to conduct a Product Recall of any Licensed Product Commercialized or otherwise distributed by or for Purdue, any Affiliate thereof, or any Sublicensee in the Territory or if a voluntary Product Recall of any such
Licensed Product in the Territory is contemplated by Purdue, any Affiliate thereof, or any Sublicensee, Purdue shall immediately notify BDSI in writing of the same. BDSI will notify Purdue of any voluntary or mandatory product recall of which BDSI
becomes aware in respect of the Licensed Product in any jurisdiction other than the Territory. 
 Section 12.02 Product Recall
Management. Purdue shall have the right to control and/or conduct any Product Recall of any Licensed Product Commercialized or otherwise distributed by or for Purdue, any Affiliate thereof, or any Sublicensee in the Territory, subject to
Section 12.01. Purdue will conduct such Product Recall in a Commercially Reasonable manner determined by Purdue in its sole discretion and in compliance with all Applicable Law. Purdue, its Affiliates or Sublicensees, as applicable, shall
maintain records of all sales and distribution of Licensed Products and customers in the Territory sufficient to reasonably adequately administer a Product Recall, for the period required by Applicable Law, and make such records available to BDSI or
any designee thereof immediately upon request. BDSI shall cooperate, at, except as otherwise set forth in the Supply Agreement, Purdue’s expense, in the conduct of any Product Recall for such Licensed Product in the Territory as reasonably
requested by Purdue. In the event Purdue notifies BDSI, or BDSI otherwise becomes aware, that Purdue, any Affiliate thereof, or any Sublicensee does not intend to undertake a Product Recall (i) in respect of any death or life-threatening
Adverse Event associated with any Licensed Product or (ii) to comply with any Applicable Law with respect to any Licensed Product within, in either case, a reasonable period of time, or is unreasonably delayed in undertaking any such Product
Recall, BDSI shall be entitled to do so without Purdue’s prior written consent, in which case Purdue shall cooperate (and cause its Affiliates and Sublicensees to cooperate) in the conduct of any such Product Recall as reasonably requested by
BDSI. 
 Section 12.03 Product Recall Costs. Purdue shall, except to the extent set forth in the Supply Agreement, bear
all costs and expenses related to the conduct of any Product Recall of any Licensed Product Commercialized or otherwise distributed by or for Purdue, its Affiliates or Sublicensees in the Territory. 

  
 42 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 Section 12.04 Notification of Relevant Events. Throughout the duration of
this Agreement, the Parties shall keep each other reasonably informed about any material adverse events, side effects, injury, toxicity or sensitivity reaction associated with the Licensed Products of which such Party becomes aware, whether or not
any such effect is attributable to the Licensed Products. Purdue shall be responsible for reporting relevant side effects to the appropriate Competent Authorities in the Territory in accordance with Applicable Laws. Each Party shall promptly inform
the other Party by telephone and in writing in the event any circumstances occur which may reasonably precipitate a possible or actual recall of any Licensed Products. Throughout the duration of this Agreement and with respect to all Licensed
Products, the Parties shall immediately notify each other of any information a Party receives regarding any threatened or pending action, inspection or communication by or from a concerned Governmental Authority which may affect the safety or
efficacy claims of the Licensed Products or the continued marketing of the Licensed Products. 
 ARTICLE XIII 

TERM AND TERMINATION 

Section 13.01 Term. This Agreement shall commence as of the Effective Date and expire on the later of (a) the first
date on which there is not at least one Valid Claim of the Licensed Patents in the Territory Covering any Licensed Product or (b) February 14th of the Calendar Year immediately following
the first complete Calendar Year following the tenth (10th) anniversary of First Commercial Sale in which Net Sales total less than CA$*** (such period, the “Term”). Licensee shall provide written notice to BDSI as soon as
reasonably possible, but in any event within ***, following the end of the first complete Calendar Year following the tenth (10th) anniversary of First Commercial Sale in which Net Sales total less than CA$***. 

Section 13.02 Termination by Either Party for Cause. Subject to Section 13.06, a Party may terminate this Agreement
prior to the expiration of this Agreement upon the occurrence of any of the following: 
 (a) upon or after the permanent cessation of
operations of the other Party without a successor, or the bankruptcy or judicially declared insolvency of such Party, or the dissolution or winding up of the other Party (other than dissolution or winding up for the purposes or reconstruction or
amalgamation) without a successor; or 
 (b) upon or after the material breach of this Agreement or the Supply Agreement by the other Party
(other than a failure to pay by Purdue under this Agreement, which is addressed in Section 13.03(b)), if the breaching Party has not cured such breach, if capable of being cured within such time period, within *** after written notice thereof
by the non-breaching Party, provided that notwithstanding the foregoing, BDSI shall be entitled to terminate this Agreement pursuant to Section 13.03(b) without providing the aforementioned opportunity to cure. 

  
 43 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 Section 13.03 Termination by BDSI. Subject to Section 13.07, BDSI
may, by written notice to Purdue, terminate this Agreement: 
 (a) upon the failure by Purdue to pay the license fee pursuant to
Section 3.01 within the time period set forth therein; 
 (b) upon the failure by Purdue on *** occasions to pay any amount overdue
under this Agreement within *** from receipt of a written notice thereof to Purdue from BDSI (with respect to any amounts due under this Agreement pursuant to an invoice to be sent by BDSI, the first such invoice shall not be deemed
“notice” for purposes of this paragraph), provided that any failure to pay resulting from any Third Party delays with respect to the transfer of funds from Purdue to BDSI that are out of the reasonable control of Purdue and its Affiliates
(such as bank transfer delays) shall not constitute a “failure to pay” for purposes of this clause (b); or 
 (c) in the event the
First Commercial Sale of a Licensed Product hereunder does not occur by the date nine (9) months from Marketing Authorization Transfer, provided that, to the extent that Purdue can reasonably demonstrate that manufacturing or supply delays
outside of Purdue’s, its Affiliates’, and Sublicensees’ reasonable control prevented the First Commercial Sale from occurring by such date, such date shall be automatically extended by an amount equal to the extent of such
manufacturing or supply delays. 
 Section 13.04 Discretionary Termination by Purdue. 

(a) Purdue shall have the right to terminate this Agreement upon *** written notice to BDSI if, as determined by Purdue in its
sole discretion, general market conditions indicate that the Licensed Product is not economically viable for Purdue in the Territory. 

(b) BDSI shall notify Purdue in writing at least *** in advance of any Adverse BDSI Acquisition. Purdue shall have the right
to terminate this Agreement on *** notice given by Purdue up to *** after the consummation of such Adverse BDSI Acquisition. 

Section 13.05 Remedies. All of a non-breaching Party’s remedies with respect to a breach of this Agreement shall be
cumulative, and the exercise of one remedy under this Agreement by the non-breaching Party shall not be deemed to be an election of remedies. These remedies shall include the non-breaching Party’s right to sue for damages for such breach
without terminating this Agreement and to seek such other remedies as may be available to such Party at law or in equity. 

  
 44 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 Section 13.06 Effect of Termination. 

(a) Upon any expiration or termination of this Agreement, and subject to Section 13.06(b) and the exercise of the rights granted
thereunder, (i) the rights granted under Sections 3.02 and 3.03 with respect to the Licensed Marks and the Licensed Technology, and any sublicenses granted thereunder, shall terminate, (ii) Purdue and its Affiliates shall
(A) immediately transfer to BDSI all information in Purdue’s and its Affiliates’ possession concerning Licensed Products, Licensed Product inventory and work-in-process, Purdue Know-How, Purdue Patents, Purdue Marks, Purdue
Documentation, Product-Related Materials, Regulatory Filings, Marketing Authorizations, and Governmental Approvals, including but not limited to any market research and competitive reports, marketing reports, and related data concerning Licensed
Products or the Commercialization thereof in the Territory, and, if and as subsequently requested by BDSI in writing, (B) transfer and assign to BDSI all right, title, and interest in all Regulatory Filings, Marketing Authorizations, DINs, and
Governmental Approvals, and Product-Related Materials (other than Purdue’s right, title or interest in or to any Purdue Know-How, Purdue Patents, Purdue Marks or any other Purdue intellectual property rights embodied in any of the foregoing),
and Purdue will take, without delay, the steps required to effect re-assignment of the DINs to BDSI or a designee thereof, including by communicating the change in ownership to the relevant Competent Authority, (iii) Purdue shall, to the extent
requested by BDSI, sell and deliver the inventory of Licensed Products and work-in-process to BDSI, and BDSI shall, within *** of such delivery, pay Purdue an amount to be negotiated and agreed upon by the Parties that shall not exceed Purdue’s
reasonable, documented, direct cost of procuring such inventory or work-in-process, provided that, if BDSI exercises such right, BDSI will, if requested by Purdue and agreed to in writing by BDSI, assume Purdue’s obligations to Third Parties in
the Territory with respect to the sale or distribution of such Licensed Product, subject to, and as shall be further detailed in, any such agreement between the Parties, (iv) Purdue hereby grants BDSI and its Affiliates the perpetual,
irrevocable, royalty-free, fully-paid, exclusive right and license, transferable with this Agreement under Section 14.01 and with rights of sublicense, under the Purdue Know-How and Purdue Patents, and a perpetual, irrevocable, royalty-free,
fully-paid license, transferable with this Agreement under Section 14.01 and with rights of sublicense, under the Purdue Marks, to develop, make, have made, use, sell, offer for sale, import, and export, market and promote Licensed Products and
Demonstration Samples in the Territory (including but not limited to all Licensed Products Commercialized or under development by Purdue or any of its Affiliates or Sublicensees as of the effective date of termination), including the right to use
all marketing, promotional and similar materials related solely to the Licensed Product that are in Purdue’s, its Affiliates’, or its Sublicensees’ Control, and (v) Purdue shall provide BDSI all information requested by BDSI
concerning any manufacturing, supplier, distributor, research, development, clinical study, or other contracts concerning the Development, manufacture, or Commercialization of Licensed Products or Demonstration Samples entered into by Purdue or its
Affiliates with Third Parties (“Product-Related Contracts”) and information related to any of the foregoing to the extent permitted by the terms thereof (and, if not so permitted, Purdue shall use reasonable efforts to obtain such
permission and thereafter disclose to the extent enabled by such permissions) and, if and as subsequently requested by BDSI, (X) assign such Product-Related Contracts to BDSI (to the extent assignable in accordance with their terms or consent
to such assignment is obtained by Purdue pursuant to the following clause (Y)), (Y) use Commercially Reasonable Efforts to obtain Third Parties’ consent to such assignment to the extent not permitted by the terms of such

  
 45 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
agreements, in order to enable such assignment as contemplated by clause (X), or (Z) otherwise reasonably facilitate BDSI’s establishment of similar relationships with such Third
Parties. BDSI shall reimburse all of Purdue’s and its Affiliates’ reasonable, documented out-of-pocket costs in performing its obligations under clause (ii)(B) (except in the case of a termination of this Agreement by BDSI pursuant to
Section 13.02 or 13.03 or by Purdue under Section 2.01(d), 6.04, or 13.04, in which case BDSI shall not have any such obligation) and clause (iv) above, provided that, in the case of clause (iv), (A) such costs shall only include
reasonable, documented royalties or other licensing fees paid by Purdue and its Affiliates to Third Party licensors as a direct and sole result of BDSI’s exercise of rights or sale of Licensed Product in the Territory under any applicable
license to Purdue from a Third Party and (B) BDSI has been provided full and complete information regarding such costs in advance with a reasonable opportunity to decline to be granted or terminate such a sublicense. 

(b) Upon any expiration of this Agreement or termination of this Agreement other than by BDSI pursuant to Section 13.02 or 13.03, or as
permitted in writing by BDSI in the event of any termination by BDSI pursuant to Section 13.02 or 13.03, Purdue (and/or its Affiliates and Sublicensees, if and as applicable) shall have the right, for a period of twelve (12) months from
the date of termination to distribute and sell existing inventory of Licensed Products subject to the terms of this Agreement (including Article IV hereof and the payment of royalties thereunder) to the extent such inventory is not purchased by BDSI
pursuant to Section 13.06(a)). 
 (c) Except as otherwise provided in this Agreement, expiration or termination of this Agreement shall
not relieve the Parties of any obligation accruing prior to such expiration or termination. Except as set forth below or elsewhere in this Agreement, the obligations and rights of the Parties under Articles I and IV and Sections 3.02(c), 3.05, 3.06,
8.01, 8.02, 8.03, 9.12, 10.01, 10.02, 10.03. 10.04 (to the extent set forth therein), 10.05, 11.01, 11.03, 11.07, 11.11, 12.01, 12.02, 12.03, 13.05, 13.06, 13.08, 14.01, 14.02, 14.03, 14.04, 14.05, 14.06, 14.07, 14.08, 14.09, 14.10, 14.11, 14.12,
14.13, and 14.14 shall survive expiration or termination of this Agreement. 
 (d) Subject to the provisions of this Section 13.06, and
except as necessary to enable the exercise of any rights granted under this Agreement or perform any obligations under this Agreement following its expiration or termination, within *** following the expiration or termination of this Agreement, each
Party shall return to the other Party, or destroy, upon the written request of the other Party, any and all Confidential Information of the other Party in its possession and upon a Party’s request, such destruction (or delivery) shall be
confirmed in writing to such Party by a responsible officer of the other Party. 
 Section 13.07 Suspension of Cure Period
Pending Dispute Resolution. If a Party gives notice of breach under Section 13.02 or Section 13.03 and the other Party, acting in good faith, disputes in writing prior to the end of the applicable cure period whether such
notice was proper, then the issue of whether a material breach has occurred shall be resolved in accordance with Section 14.03. If as a result of such dispute resolution process it is determined that the notice of breach was proper, then such
notice shall be deemed to have been effective if the breaching Party fails thereafter to cure such breach in accordance with the determination made in the resolution 

  
 46 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
process within the applicable cure period following such determination. If as a result of such dispute resolution process it is determined that the notice of breach was improper, then no such
notice shall be deemed to have been effective and this Agreement shall remain in effect. All of the terms and conditions of this Agreement, including all of the licenses granted hereunder, shall remain in full force and effect during the pendency of
such dispute resolution process. 
 Section 13.08 Bankruptcy of BDSI. The rights granted to Purdue and BDSI in Article
III and Section 13.06 are intended by the Parties to be grants of a right to “intellectual property,” as defined under Section 101(35A) of the U.S. Bankruptcy Code. The Parties intend for the protections of section 365(n) of the
U.S. Bankruptcy Code (and any corresponding or similar protections under similar laws in the Territory) to apply to such licenses granted herein and nothing in the this Agreement limits a Party’s rights with respect thereto under section 365(n)
of the U.S. Bankruptcy Code or such similar laws in the Territory; and if a Party’s obligations under the license are terminated in bankruptcy, such Party shall receive a copy of all applicable intellectual property (and embodiments thereof).

 ARTICLE XIV 

MISCELLANEOUS 

Section 14.01 Assignment. Except as explicitly contemplated by this Agreement, neither this Agreement nor any rights or
obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld); provided, however, that, notwithstanding anything to the
contrary, either Party may assign this Agreement and its rights and obligations hereunder without the other Party’s consent (a) to any of the assigning Party’s Affiliates, including pursuant to a reorganization of such Party’s
organizational structure solely for tax purposes, (b) in connection with the transfer, sale, or other disposition of all or substantially all of the assets or business of such assigning Party (or that portion thereof, or any portion of any
product, to which this Agreement relates) to a Third Party, whether by merger, sale of stock, sale of assets or otherwise, or (c) for the benefit of a creditor or, in the event of any exercise of any remedies by a creditor, to a purchaser in a
foreclosure sale of collateral (subject to assumption by such purchaser of all obligations under this Agreement). Notwithstanding the foregoing, any such assignment to an Affiliate shall not relieve the assigning Party of its responsibilities for
performance of its obligations under this Agreement, so long as such Affiliate remains an Affiliate of the assigning Party. Each Party shall promptly notify the other Party of any purported assignment of this Agreement. The rights and obligations of
the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties. Any purported assignment not in accordance with this Agreement shall be void. 

Section 14.02 Force Majeure. Neither Party shall be held liable or responsible to the other Party nor be deemed to have
defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement to the extent such failure or delay is caused directly by or results directly from causes beyond the reasonable control of the
affected Party, including, but not limited to, fire, floods, embargoes, terrorism, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor

  
 47 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
disturbances, acts of God or acts, omissions, delays, or actions by any Governmental Authority or for any other reason which is completely beyond the reasonable control of the Party (other than
by reason of such Party failing to comply with Applicable Law) (collectively a “Force Majeure”). The Party prevented from carrying out its obligations hereunder shall give written notice to the other Party of an event of Force
Majeure upon it being reasonably foreseen with reasonable certainty by, or becoming known to, the affected Party, such notice to describe the cause and estimated effect of the event of Force Majeure. If and to the extent that a Party is delayed or
prevented from performing its obligation under this Agreement, other than a payment of monetary obligations, due to a Force Majeure, such Party shall nonetheless use its Commercially Reasonable Efforts to mitigate, avoid or end such delay or failure
in performance to the extent and as soon as reasonably practicable. 
 Section 14.03 Governing Law; Jurisdiction; Dispute
Resolution. 
 (a) This Agreement shall be governed by and construed under the state laws of the State of New York, without
reference to its conflicts of laws principles. 
 (b) In the event that any controversy or claim shall arise between the Parties under, out
of, in connection with, or relating to this Agreement or the breach thereof, the Party initiating such controversy or making such claim shall provide to the other Party written notice containing a brief and concise statement of the initiating
Party’s claims, together with relevant facts supporting them. During a period of ***, or such longer period as may be mutually agreed upon in writing by the Parties, following the date of said notice, the Parties shall make good faith efforts
to settle the dispute. Such efforts may include, but shall not be limited to, full presentation of both Parties’ claims and responses, with or without the assistance of counsel, before the chief executive officers (or their designees) of the
Parties. If for whatever reason the Parties are unable to resolve the dispute within *** after the issuance of a notice of dispute, then either Party may, by written notice to the other Party, submit the dispute to binding arbitration in accordance
with the provisions of Section 14.03(c). 
 (c) In the event that the Parties have been unable to reach accord using the procedures set
forth in Section 14.03(b), either Party may seek final resolution of the matter through binding arbitration upon written notice to the other Party. The failure of a Party to comply with the provisions of Section 14.03(b) with respect to
any controversy or claim shall, except as set forth in Section 14.03(d), constitute an absolute bar to the institution of any proceedings, by arbitration or otherwise, by such Party with respect to such controversy or claim. Any such
arbitration shall be held in a location that is mutually agreed upon by the Parties, which provides neither party an advantage (or, if the Parties are unable to agree on a location within *** of the initiation of arbitration hereunder, such location
shall be New York, New York), in the English language before a single independent, neutral arbitrator, who shall be selected by agreement of the Parties, or, if the Parties cannot agree within *** after commencement of arbitration, then by the
American Arbitration Association (“AAA”) in accordance with the then existing Commercial Arbitration Rules of the AAA (the “Rules”) and judgment upon the award rendered by the arbitrator may be entered or enforced
in any court having jurisdiction thereof. The arbitrator shall have at least *** experience in pharmaceutical patent licensing. The arbitrator shall permit the Parties to have discovery to the extent permitted by the Rules. The

  
 48 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
decision of the arbitrator shall be final and binding on the Parties and shall be accompanied by a written opinion of the arbitrator explaining the arbitrator’s rationale for its decision.
Except as may otherwise be determined by the arbitrator in its award to be just and appropriate in light of the particular circumstances and outcome of the arbitration, the Party losing the arbitration shall pay all fees and costs of the arbitrator
and the AAA and reimburse the prevailing Party for its reasonable attorneys’ fees, costs, expenses, and disbursements (including, for example, expert witness fees and expenses, photocopy charges and travel expenses). The intent of the Parties
is that, except for the entering of an arbitration order in a court of competent jurisdiction or as set forth in Section 14.03(d), disputes shall be resolved finally in arbitration as provided above, without appeal, and without recourse to
litigation in the courts. 
 (d) Notwithstanding the foregoing provisions of this Section 14.03, (i) each Party shall be entitled
to seek injunctive or equitable relief to enforce the respective covenants and agreements of the Parties in this Agreement and (ii) either Party may initiate an action before any court having competent jurisdiction in order to obtain interim or
conservatory relief, such as an order to preserve the status quo and to avoid incurring irreparable harm pending the resolution of any dispute that is submitted to arbitration, to prevent or enjoin, without in either case complying with the
procedures set forth in Section 14.03(b) or 14.03(c). 
 Section 14.04 Waiver. No waiver of any term or condition of
this Agreement shall be effective unless set forth in a written instrument duly executed by or on behalf of the waiving Party. Except as specifically provided for herein, the waiver from time to time by either of the Parties of any of their rights
or their failure to exercise any remedy shall not operate or be construed as a continuing waiver of same or of any other of such Party’s rights or remedies provided in this Agreement. 

Section 14.05 Severability. In case any provision of this Agreement shall be invalid, illegal or unenforceable, the
validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. Any provision of this Agreement held invalid or unenforceable in part or degree will remain in full force and effect to the
extent not held invalid or unenforceable. 
 Section 14.06 Notices. All notices and other communications provided for
herein shall be dated and in writing and shall be deemed to have been duly given (a) on the date of delivery, if delivered personally, by e-mail or by facsimile machine, receipt confirmed, (b) on the following business day, if delivered by
a nationally recognized overnight courier service, with receipt acknowledgement requested, or (c) three (3) business days after mailing, if sent by registered or certified mail, return receipt requested, postage prepaid, in each case, to
the Party to whom it is directed at the following address (or at such other address as any Party shall hereafter specify by notice in writing to the other Parties): 

  
 49 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

			
	 If to BDSI:
	 	BioDelivery Sciences International, Inc.
		 	4131 Parklake Avenue, Suite #225
		 	Raleigh, North Carolina 27612
		 	Attn: Mark Sirgo, Chief Executive Officer
		 	Telephone: 919-582-9050
		 	Facsimile: 919-582-9051

  

			
	 Copies (which shall not constitute notice) to:
	 	 Wyrick Robbins Yates & Ponton LLP

		 	 4101 Lake Boone Trail, Suite 300

		 	 Raleigh, North Carolina 27607 USA

		 	 Attn: Jason S. Wood

		 	 Telephone: (919) 781-4000

		 	 Facsimile: (919) 781-4865

 

			
	 If to Purdue:
	 	 Purdue Pharma

		 	 575 Granite Court

Pickering, ON

L1W 3W8

Attn: Dr. Craig Landau, President & CEO

Telephone: 905-421-3356

Facsimile: 905-420-4193

	
	 Copies (which shall not constitute notice) to:

		
		 	 Purdue Pharma

575 Granite Court

Pickering, ON

L1W 3W8

Attn: Jacqueline LeSaux, Vice President, Legal

Telephone: 905-420-4958

Fax: 905-420-4193

 Section 14.07 Independent Contractors. It is expressly agreed that BDSI and Purdue shall be
independent contractors and that the relationship between the two Parties shall not constitute a partnership or agency of any kind. Neither BDSI nor Purdue shall have the authority to make any statements, representations or commitments of any kind,
or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party. 

Section 14.08 Rules of Construction. The Parties agree that they have been represented by counsel during the negotiation
and execution of this Agreement and, therefore, waive the application of any applicable law, regulation, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the Party drafting such
agreement or document. Whenever the context hereof shall so require, the singular shall include the plural, the male gender shall include the female gender and neuter, and vice versa. 

  
 50 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 Section 14.09 Publicity. Neither Purdue nor BDSI will make any public
announcement in respect of this Agreement or the matters contemplated hereby without the other Party’s prior written approval, such approval not to be unreasonably withheld, except as may be required by applicable law, rule, or regulation or
the rules and regulations of the Securities and Exchange Commission, any national securities exchange (including those located in countries outside of the United States) or the Nasdaq Stock Market, and provided that, notwithstanding anything to the
contrary, BDSI shall be entitled to announce or disclose that BDSI has earned any of the milestone payments described under Section 4.02 (which announcement may describe the triggering milestone event). Where a public announcement or disclosure
is required by required by applicable law, rule, or regulation or the rules and regulations of the Securities and Exchange Commission, any national securities exchange (including those located in countries outside of the United States) or the Nasdaq
Stock Market, or if BDSI is announcing or disclosing that BDSI has earned any of the milestone payments described under Section 4.02 (which announcement may describe the triggering milestone event), the Party required to make the announcement
or disclosure or BDSI, respectively, will, to the extent reasonably practicable, reasonably in advance of such announcement or disclosure (1) inform the other Party of the contents of the proposed announcement and (2) afford the other
Party a reasonable opportunity to comment on the announcement or disclosure in draft form. Notwithstanding the foregoing, no consent of any Party shall be required to release information which has previously been made public. Notwithstanding, and
without limitation of, the foregoing, both Parties shall use reasonable good faith efforts to agree on a press release to be issued promptly following the execution of this Agreement. Any notice to or request for approval to be made pursuant to this
Section 14.09 shall be made in accordance with Section 14.06, or by email to *** for Purdue or *** for BDSI, except that in the case of notices to or requests for approval from Purdue, a copy of such notices or requests for approvals shall
also be directed to, in addition to those persons named in Section 14.06, ***. 
 Section 14.10 Entire Agreement;
Amendment. This Agreement (including the Exhibits attached hereto), the Supply Agreement and, upon execution thereof by the Parties, the Quality Agreement and the Pharmacovigilance Agreement sets forth all of the covenants, promises,
agreements, warranties, representations, conditions and understandings between the Parties with respect to the subject matter hereof and supersedes and terminates all prior agreements and understandings between the Parties. There are no covenants,
promises, agreements, warranties, representations conditions or understandings, either oral or written, between the Parties other than as set forth herein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding
upon the Parties unless reduced to writing and signed by the respective authorized officers of the Parties. 
 Section 14.11
Audit and Inspection Rights. Upon *** prior written notice from either Party (the “Requesting Party”), the Party receiving such notice (the “Audited Party”) shall permit an independent certified public
accountant selected by the Requesting Party (or any designee thereof) and reasonably acceptable to the Audited Party (with respect to inspections or audits directly concerning financial matters) or any designee selected by the Requesting Party and
reasonably acceptable to the Audited Party (with respect to inspections or audits not directly concerning financial matters) to audit and/or inspect only those Books and Records (including 

  
 51 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
  

 
but not limited to financial records) as may be necessary pursuant to the terms of the applicable Section of this Agreement granting the applicable audit and/or inspection rights to the
Requesting Party pursuant to this Section 14.11. For greater certainty, the Audited Party shall not disclose, nor be required to disclose, to the independent accounting firm, and the independent accounting firm shall not audit, inspect or
disclose to the Requesting Party, any competitively sensitive or strategic information of the Audited Party to the extent directly and solely related to any product other than the Licensed Product and/or any jurisdiction other than the Territory.
Any such independent accounting firm or designee shall be subject to the confidentiality provisions of this Agreement. In the case of any audit and/or inspection directly concerning financial matters, a copy of any report provided to a Party by the
accountant shall be given concurrently to the other Party and shall be considered the Audited Party’s Confidential Information. Subject to the terms of this paragraph, any such inspection or audit shall be conducted (a) at the sole cost of
the Requesting Party and (b) during the Audited Party’s normal business hours. If the applicable audit involves payments made and/or to be made by one Party to the other Party and such accounting firm concludes that there was an
overpayment or underpayment by one Party to the other Party with respect thereto, within *** of the date of delivery of such accounting firm’s report concluding that an overpayment or underpayment occurred, the amount overpaid shall be promptly
repaid by the overpaid Party or the amount underpaid shall be promptly augmented by the underpaying Party as necessary to correct the underpayment, and if there was an underpayment, the underpaying Party shall pay interest on the unpaid amount at
the rate set forth in Section 4.03(c). If the amount of such underpayment for any particular Calendar Quarter was equal to or greater than *** of the proper amount payable with respect to such Calendar Quarter, the Audited Party shall promptly
reimburse the Requesting Party for the reasonable, documented costs associated with the audit. 
 Section 14.12 Headings.
The captions contained in this Agreement are not a part of this Agreement, but are merely guides or labels to assist in locating and reading the several Articles hereof. 

Section 14.13 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. Signatures to this Agreement may be transmitted via email or facsimile and such signatures shall be deemed to be originals. 

Section 14.14 CREATE Act This Agreement includes a joint research agreement as defined in 35 U.S.C. § 103(c)(3). 

[Signature page to follow.] 

  
 52 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed in duplicate by their
duly authorized officers as of the Effective Date. 
  

			
	ARIUS PHARMACEUTICALS, INC.

			
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

  

			
	BIODELIVERY SCIENCES INTERNATIONAL, INC.

			
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

  

			
	PURDUE PHARMA
	
	By its general partner, PURDUE PHARMA INC.

			
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

 Signature page to License Agreement 

 EXHIBIT A 

INITIAL BDSI TPMCXA 
  

			
	 Dosage Strength of Licensed
Product
	  	 Initial BDSI
TPMCXA

		
	 *** mcg
	  	US$***
	 *** mcg
	  	US$***
	 *** mcg
	  	US$***
	 *** mcg
	  	US$***
	 *** mcg
	  	US$***
	 *** mcg
	  	US$***
	 *** mcg
	  	US$***

 EXHIBIT B 

LICENSED MARKS 
  

									
	 Mark
	  	 Application No./Date
	  	 Registration No./Date
	  	 Renewal Date
	  	 Goods

					
	 BELBUCA
	  	 1,694,096

09/16/2014
	  	 TMA932,689

03/29/2016
	  	03/29/2031	  	Pharmaceutical preparations, namely analgesics.

 EXHIBIT C 

LICENSED PATENTS 
  

													
	 Appln. No.
	  	 Status
	  	 Filing Date
	  	 Patent No.
	  	 Issue Date
	  	 Exp. Date
	  	 Assignee

							
	 2268187
	  	Granted	  	16-Oct-1997	  	2268187	  	05-Jun-2007	  	16-Oct-2017	  	Arius Two, Inc.
							
	 2658585
	  	Granted	  	20-Jan-2009	  	2658585	  	01-Mar-2011	  	23-Jul-2027	  	BioDelivery
Sciences
International,
Inc.
							
	 2859859
	  	Pending	  	18-Jun-2014	  		  		  		  	BioDelivery
Sciences
International,
Inc.

 EXHIBIT D 

LICENSED MARK GUIDELINES 

1. The Licensed Marks must only be used in accordance with the applicable registrations set forth in Exhibit B of this
Agreement.
 2. Each Licensed Mark should always be used in its entirety. Do not dissect any Licensed Mark into separate parts.

3. Each Licensed Mark must never be confused or blurred by printing it over additional design elements as distracting color overlays,
ornamentation, textures or photographs in such a manner that a reasonable person would be unable to read or distinguish the Licensed Mark. 

4. All goods displaying a Licensed Mark must maintain the highest possible quality. Do not use the Licensed Mark in connection with
products or services inferior to the quality of other products and services bearing the Licensed Mark.
 5. Do not use a Licensed Mark in
any manner that will reflect adversely upon the goodwill and reputation associated with such Licensed Mark, any Licensed Product, or BDSI. 

6. Each Licensed Mark is a noun and should not be used in print or verbally as an adjective, a verb or other part of speech. 

7. The ® symbol should be displayed next to a Licensed Mark if the Licensed Mark is
registered. Otherwise, the TM symbol should be used. 
 8. Each Licensed Marks should only be used to refer to the Licensed
Product. 
 9. The Licensed Marks should never be used in a way that is misleading or may imply association of unrelated products or
companies. 
 10. Where typically included, use of any Licensed Mark should be accompanied by the following statement: “[Licensed Mark]
is a registered trademark of BioDelivery Sciences International, Inc., used with permission by Purdue Pharma.” 

 EXHIBIT E 

*** 

 EXHIBIT F 

ENDO HEALTH CANADA LETTER 

*** 

 SCHEDULE 2.01(D) 

INITIAL NOC FEE AMOUNT 

*** 

 SCHEDULE 5.01(A) 

COMMERCIALIZATION EFFORTS 

***

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}]]